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The measurement of tissue biomarkers for therapeutic response prediction in cancer
patients has become standard pathological practice, but only for a very limited
number of targets. This is in spite of massive intellectual and financial investment in
molecular pathology for translational cancer research. A re-evaluation of current
approaches, and the testing of new ones, is required in order to meet the challenges
of predicting responses to existing and novel therapeutics, and individualising
therapy.
Herein I critique the current state of tissue biomarker analysis and quantification in
cancer pathology and the reasons why so few novel biomarkers have entered the
clinic. In particular, we examine the central role of signalling pathway biology in
sensitivity and resistance to targeted therapy. I discuss how accurate quantification,
and the ability to simulate biological responses over time and space, may lead to
more accurate prediction of therapeutic response. I propose that different
mathematical techniques used in the nascent field of systems biology (ordinary
differential equation-based, S-systems, and Bayesian approaches) may provide
promising new avenues to improve prediction in clinical and pathological practice. I
also discuss the challenges and opportunities for quantification in pathological
research and practice.
I have examined the role of cellular signalling pathways in therapeutic sensitivity and
resistance in three different ways. Firstly, I have taken a hypothesis-driven and
reductionist approach and shown that decreased Sprouty 2, a feedback inhibitor of
MAPK and PI3K signalling, is associated with trastuzumab-resistance in vitro and in
a cohort of breast cancer patients treated with trastuzumab. Secondly, I have
characterised the activation state of ten growth and survival pathways across
different histological subtypes of ovarian cancer using quantitative fluorescence
microscopy. I have shown that unsupervised clustering of phosphoprotein expression
profiles results in new subgroups with distinct biological properties (in terms of
proliferation and apoptosis), and which predict therapeutic response to
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chemotherapy. Thirdly, I have developed a new mathematical model of PI3K
signalling, parameterised using quantitative phosphoprotein expression data from
cancer cell lines using reverse-phase protein microarrays, and shown that quantitative
PTEN protein expression is the key determinant of resistance to anti-HER2 therapy
in silico. Furthermore, the quantitative measurement of PTEN is more predictive of
response than other pathway components taken in isolation and when tested by
multivariate analysis in a cohort of breast cancers treated with trastuzumab. For the
first time, a systems biology approach has successfully been used to stratify patients
for personalised therapy in cancer, and is further compelling evidence that PTEN,
appropriately measured in the clinical setting, refines clinical decision-making in
patients treated with anti-HER2 therapies.
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The published literature is awash with examples of new tissue biomarkers promising
to predict responses to therapy in cancer patients. However, few of these progress
from the laboratory to the clinic. An exception to this is biomarker quantification in
breast cancer, where oestrogen receptor (ER) and HER2 expression are both
measured routinely in clinical practice by immunohistochemistry. In this chapter we
discuss some of the reasons why more tissue biomarkers proposed in the research
setting have not entered the clinic, using breast cancer biomarker development to
illustrate. We discuss a selection of biomarkers which are in development and which
may be candidates for clinical application using standard molecular pathology
techniques, such as immunohistochemistry or fluorescence in situ hybridisation,
within the next few years (eg. topoisomerase II, EGFR, AKT, PTEN). In particular,
we explore how our ever increasing knowledge of molecular and pathway biology is
facilitating hypothesis-driven biomarker discovery, and the statistical considerations
which need to be addressed in order to adequately validate new candidate
biomarkers.
1.2 Introduction
In the last 35 years only two molecular markers, oestrogen receptor (ER) and HER2,
have become standard measurements in the management of breast cancer patients
(1;2). The long evolutionary cycle of predictive biomarkers seems at odds with the
number of published articles on the subject, suggesting the need for a new, and more
rigorous approach to this area (3). At the time of writing a simple literature search for
'predictive markers in breast cancer' returns over 150 papers in English in the last
year alone, which represent over twenty new molecules, all of which associate with
disease-free or overall survival reflecting the bias towards identification of "novel"
markers and the lack of investment (both financial and intellectual) in translation of
these findings into clinical settings. In spite of massive investment in biomarker
discovery, only one new biomarker has been translated into clinical practice in the
past twenty five years (HER2). The aim of this chapter, therefore, is not to provide a
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comprehensive overview of candidate predictive biomarkers but to explore the
driving forces behind biomarker application and discovery, the techniques which are
being used in biomarker validation, and the considerations which need to be taken
into account in order for new biomarkers to be a clinical success. We will illustrate
the 'hottest' biomarker research topics along the way, which with appropriate and
directed research effort, may form part of clinical diagnostic decision-making over
the next 3-5 years using the tools currently available in standard histopathology
laboratories.
1.3 Drug-driven tissue biomarker discovery
The success of the archetypal predictive biomarkers ER and HER2 in breast cancer
was driven by the availability of agents and knowledge of how they interact with
their targets. There has been limited evidence over the past 20 years of the
application of similar mechanistically targeted biomarker discovery approaches.
However, the same rational pharmacotherapy paradigm is gradually being applied to
both existing chemotherapeutic agents as knowledge of their mechanism of action
emerges, and newer targeted "biological agents" as molecular biology is factored
into early phase trials during the development of novel pharmacological agents
1.3.1 Existing agents - teaching old dogs new tricks
The current thinking within clinical oncology is that, whilst biologically targeted
agents offer significant hope for the future, at least for the next 5-10 years, these
agents are likely to be targeted either on specific sub-groups of patients, as with
trastuzumab, and/or given in combination with conventional chemotherapeutic
agents, as with Avastin. There remains, therefore, a significant debate as to the
optimum scheduling and combination of current chemotherapeutic and endocrine
agents, which is fuelled by two distinct thought processes. Firstly, it is clear that
many patients who receive systemic therapy for breast cancer do not, in fact require
such treatment (Oxford overview (4)). It is an inability to identify such patients prior
to treatment, rather than an expectation that all patients derive benefit, which drives
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the treatment of significant numbers of breast cancer patients with often aggressive
chemotherapy. The identification of novel prognostic markers (ie markers which
inform about clinical response in the absence of therapy) is key to the solution of this
dilemma. Secondly, it is becoming increasingly apparent that the biological diversity
of breast cancer (cf gene expression signatures of Perou et al (5)) underpins not only
potential differences in the natural history of the disease but also differences in
response to current adjuvant chemotherapy regimens. Thus it is entirely possible, and
indeed highly likely, that some tumours which are insensitive to taxanes may in fact
respond to anthracycline-based chemotherapies and vice versa. Thus the search for
an optimal chemotherapy schedule and combination must in the future include the
expectation that this optimum will be different for different patient subgroups and
that these groupings will be defined by the presence within breast cancers of
molecular targets for specific chemotherapeutic agents. As a result a key objective
of research into predictive biomarkers in the near future will be the identification of
markers which identify the optimal chemotherapy regimen. This research priority
was in fact the second most important goal, second only to identification of
prognostic markers to identify patients not requiring treatment, identified in a recent
multinational focus group document aimed at identification of the top ten most
important research questions in breast cancer (The Top Ten Programme:
http://www.toptenresearch.org/).
This process has, in the past, been hampered by the lack of a cohesive approach to
the development of predictive biomarkers (3;6) and by the lack of appropriate,
clinical trials-based, sample banks in which such biomarkers must be validated.
Recently, however, significantly more emphasis has been placed upon the collection
of biological samples in the context of clinical trials. Many trials, including the UK
TACT, TACT2, TANGO, TEAM, SUPREMO and the BIG-1-98 trials have included
prospective tissue collection whilst others including ATAC and NEAT have made
significant efforts to retrospectively access tumour samples. These biorepositories
represent invaluable resources for the validation of predictive biomarker profiles.
Research is ongoing in many of these studies which either has reported or will report
in the next 1-3 years.
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Two key areas of biomarker research in breast cancer are amongst the first to be
addressed using these repositories. Firstly, is there an optimal signature for
discriminating patients who may benefit from frontline treatment with aromatase
inhibitors (AIs) from those who may derive benefit from tamoxifen followed by an
AI? Secondly, are their patients for whom either taxanes or anthracyclines may be
omitted without reducing their benefit from adjuvant chemotherapy?
Tamoxifen resistance has, for many years, been associated with gene amplification or
overexpression of the HER2 oncogene or lack of expression of the progesterone
receptor in ER positive breast tumours (l;7-9). Research in progress in the ATAC,
BIG-I-98 and TEAM trials is addressing this question (see below). Coupled with
further biomarker research (10-14) it is likely that we will, in the coming years,
finally be in a position to identify de novo endocrine resistant cancers, and possibly
to identify the optimal endocrine treatment regimen for distinct biological sub¬
groups.
For chemotherapy, key research in the TACT, TANGO and NEAT trials, within a
UK wide collaborative network, should provide insights into biomarkers relating to
benefit from taxanes and anthracyclines. Although the first anthracyline was first
discovered in the 1950s, its mechanism of action was not elucidated until 1984 (15).
Amongst other activities, anthracyclines inhibit the topoisomerase Ila (Tlla)
enzyme, which results in double stranded DNA breaks and initiates apoptosis. Since
anthracyclines have a low therapeutic index, and patients frequently experience
treatment-related cardiomyopathy and secondary leukaemias, biomarkers which
select for anthracyline-responsiveness would be of benefit in reducing morbidity in
patients receiving adjuvant chemotherapy. Several retrospective studies have
separately analysed, on the one hand, Tlla or HER2 expression, gene amplification
or deletion, and on the other, more conventional markers of response such as
proliferation (16-21). These studies suggest that Tlla aberrations, particularly
amplifications, may predict for improved outcome on anthracyline-based regimens
relative to tumors with a normal Tlla status. However, the water is muddied by the
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fact that the Tlla gene is located close to that for HER2 on chromosome 17q 12-21.
Amplification of HER2 is associated with Tlla gene aberrations (22), making it
difficult to be clear which gene is most closely associated with anthracycline
sensitivity. Previous studies suggest HER2 together with Tlla are both potential
predictive markers of anthracycline sensitivity (17;20;21 ;23-25). More recent data,
from the BR9601 trial (26), suggests that HER1 and HER3 provide additional
information when analysed with HER2. Therefore whilst Tlla remains a promising
candidate biomarker the possibility remains that HER2, or even complex molecular
panels may be of more practical value in determining eligibility for anthracyclines
(see below). Future data from the NEAT study and an ongoing meta-analysis may
provide further insights in this area.
1.3.2 Novel agents, novel approaches - the rationale for rational
biomarker-driven trials
Even though HER2 and ER have only marginally improved patient selection, by
excluding non-responders, lessons have been learned, particularly by the
pharmaceutical industry, about the need to decipher the biological basis of response
or risk seeing agents prematurely shelved. The most notable example of this is the
response of non-small cell lung cancer (NSCLC) to gefitinib (Iressa), an epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor, which showed promising
results in pre-clinical studies, but far more modest responses in clinical trials (10-
19%) (27;28). Discovery of mutations within the tyrosine kinase domain of the
EGFR in NSCLC patients showing dramatic responses to gefitinib caused much
excitement that the basis and a marker for sensitivity could be elucidated (29), but
the initial enthusiasm was tempered when it became clear that these mutations occur
at low frequency, and rarely in smokers (30), who most commonly develop the
disease. Since immunohistochemical (IHC) detection of EGFR was not associated
with gefitinib response (31 ;32), it became apparent that methods of patient selection
needed to be refined and standardised, in the same way that issues surrounding the
detection and criteria for treatment in HER2-overexpressing tumours have evolved
since early trials (33). Debate continues as to the optimal approach for selecting
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tumours likely to benefit from HER targeted therapies; high EGFR gene copy
number detected by fluorescence in situ hybridisation, gene mutation and protein
overexpression are all candidates in NSCLC (34), suggesting that similar approaches
could be explored when using EGFR-targeting agents, such as gefitinib and lapatinib,
in the treatment of breast cancer. Although the expression levels of EGFR in breast
cancer have been investigated extensively, precise estimates of figures for EGFR
'positivity' have been hampered by the methodological differences between studies,
including the use of different assays targeted against DNA, RNA, protein, and
activated phosphorylated proteins (35). However, it appears that EGFR is positive in
approximately 45% (range 14-91%) of all breast cancers (36;37), and expression is
associated with high grade, hormone-receptor negative tumours and increased in vivo
proliferation (38)'(39). Expression of EGFR is also enriched in basal-like breast
cancers and breast tumours from BRCA1 mutation carriers, with up to 70% of basal-
like breast cancers expressing EGFR (40;41). Furthermore, EGFR expression is seen
by immunohistochemistry in metaplastic breast carcinomas and in the stromal
compartment of phyllodes tumours (80% and 19% respectively) (42;43). These data
suggest that there are a number of patient groups who could benefit from EGFR-
targeted therapy. However, activating mutations within the kinase domain of EGFR
are not seen, and gene amplifications are only detected in up to 6% of invasive breast
cancers, although this increases to 25% of those with a basal-like phenotype (44).
Nevertheless, and especially due to the close association with hormone-receptor
status and the potential targeting of hormone-refractory breast cancer, EGFR-
inhibitors have been used in a number of Phase I and Phase II clinical studies (45).
Responses to single-agent therapy with gefitinib in hormone-resistant breast cancer
has been disappointing, with low clinical benefit rates terminating one trial early and
low numbers in another making interpretation of response rates difficult. Likewise,
and in spite of early data suggesting that combined therapy with gefitinib and the
aromatase inhibitor anastrozole could induce disease stabilisation in 20% of patients,
recent reports in the neoadjuvant setting have shown that gefitinib has neither a
biological nor a clinical effect when added to anastrozole (46). The majority of these
trials, however, did not select their patients prospectively on the basis of EGFR
expression status and were small, and therefore any sub-group benefit may not have
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been detected. Other members of the HER2 gene family may influence response to
therapy and clinical outcome (9;38;47) and results from single-agent studies with
lapatinib, as small-molecule inhibitor of EGFR and HER2 tyrosine kinases and
dimerisation inhibitor, in which patients are treated on the basis of biomarker
expression, are promising (48). Given the increasing knowledge of HER-family
biology, similar hypothesis-driven enrichment of patient populations to be treated
with EGFR-inhibitors should also be carried out, and detection and interpretation of
EGFR standardised.
1.4 Looking beyond the target: pathway-driven tissue biomarker
discovery
It is nai've to think we will be able to accurately stratify all patients into responders
and non-responders on the basis of single biomarker approaches, even if the
biomarker is known to be the drug target. Existing biomarkers are surrogates for
complex tumour biology in which multiple, non-linear pathways are (abnormally)
activated, within heterogeneous tissues. This means that resistance mechanisms may
occur at the level of the target itself (such as presence or absence of activating
mutations in EGFR), downstream of the target (such as loss of PTEN in Herceptin
resistance), or secondary to the heterogeneity of the tissue itself; ie not all cells
within the tumour express the target, so that the agent selects for resistant clones. In
addition, other mechanisms may contribute to the effectiveness of the agent which
are not directly related to the biology of the molecule that they inhibit, such as the
potential contribution of inflammatory responses to Herceptin efficacy.
We have already discussed the role that specific EGFR mutations may have in
gefitinib sensitivity in NSCLC. Recently, it was shown using a screening approach in
vitro that other existing RTK-inhibitors may be used to successfully target imatinib
(Glivec) resistant tumours, paving the way for mutation-specific treatment (49),
which would necessitate mutation-specific biomarker analysis. However, since most
of these mutations are probably rare events in breast cancer, there are currently two
approaches to predictive biomarker validation for new agents in clinical trials. The
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first is the 'bottom-up' approach, in which the targeted pathway is reconstructed
from the literature, and multiple candidate biomarkers tested in neoadjuvant and
adjuvant clinical trials with supporting evidence from in vitro and in vivo
experiments, although rarely in a systematic manner. The second is the 'top-down'
approach, where predictive signatures are produced from statistical analysis of gene
expression array data.
The precedent for the 'bottom-up' approach has come from the investigation of the
role of PTEN in Herceptin resistance (50;51). PTEN (phosphatase and tensin
homolog deleted on chromosome 10) is a tumour suppressor protein which is
frequently downregulated, although not usually mutated, in breast cancer (52). PTEN
opposes the action of phosphatidylinositol 3-kinase (PI3K) and downstream AKT to
attenuate signalling through this critical growth-promoting pathway, which is known
to be inhibited in response to Herceptin and contribute to its anti-tumour action (53).
Based on this knowledge of the underlying pathways, Nagata and colleagues showed
that loss of PTEN contributes to Herceptin resistance through activation of PI3K
signalling, and this has since been substantiated in other studies (50;51). This raises
the possibility that PTEN and possibly AKT/PI3Kinase signalling would be an
excellent candidate biomarker for validation in the clinical trial setting, although this
has only been tested in small numbers of patients and is yet to be tested in the context
of Phase III trials. AKT amplifications are rare in breast cancer, however a number
of PI3kinase mutations (in the PIK3CA gene) have been described (54). Therefore,
molecular profiling of the HER2/PTEN/PI3Kinase pathway should be prioritised for
future biomarker profiling in Herceptin resistance.
More recently we have taken a similar approach to predictive biomarker analysis of a
new agent being used in the treatment of breast cancer, RAD001, a mammalian
target of rapamycin (mTOR) antagonist (55-60). mTOR is a 289kDa serine/threonine
protein kinase that belongs to the phosphatidylinsotide-30H kinase related kinase
(PIKK) family. It exists in two distinct complexes within the mammalian cell, one
containing mTOR, GpL and raptor, (known as mTORCl) and the other containing
mTOR, GpL and rictor (mTORC2). These two mTOR complexes have distinct roles
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in intracellular signalling, with both direct and indirect effects on AKT activity. Both
inhibition and activation of AKT are seen, depending on which complex is inhibited.
By reconstructing the pathway and measuring activated (phosphorylated) protein
expression levels of candidate biomarkers in biopsies from patients treated with
RAD001 for two weeks prior to surgery, we have shown that pre-treatment phospho-
AKT (serine 473), but not total or phospho-mTOR, correlate with decreases in
proliferation with treatment as measured by Ki67 proliferation indices. This
counterintuitive result highlights how rational, pathway-driven biology can reveal
new targets for predictive biomarker analysis beyond measurement of the drug-target
alone. However, more sophisticated approaches to interrogating these pathways may
be required in order to adequately deconvolute the inherent biological complexity.
This is discussed in Chapter 2.
1.5 Beyond discovery - biostatistics in biomarker validation
Throughout this chapter we have highlighted contradictory results and some failings
in the journey of new biomarkers from 'bench to bedside'. We believe that one of the
key aspects of successful and speedy biomarker validation in current research and
clinical practice is to ensure the appropriate statistical test and the appropriate
statistical power is available prior to reporting of major clinical data sets, in order to
ensure robust validation and reduce misleading results. Whilst small sample sizes or
retrospective tumour studies are invaluable for hypothesis generation, it is imperative
that for biomarkers to be appropriately validated a priori hypotheses are correctly
defined and powered prior to commencing analysis.
Early reporting or reporting of inadequately powered studies, even within the context
of large phase III clinical trials, may not inform and may in fact lead to inappropriate
conclusions being drawn. This is particularly critical for studies reporting negative
findings. As with other measures of outcome, where underpowered studies in which
no evidence of benefit is observed are recognized as providing relatively little value,
10
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we need to recognize similarly rigorous interpretation must be applied to biomarker
analyses.
Two key examples illustrate this. Firstly, the potential predictive value of HER2 gene
amplification or overexpression with respect to tamoxifen treatment and the potential
for HER2 to act as a predictive biomarker for response to aromatase inhibitors. There
is extensive in vitro and in vivo evidence to support the role of HER2 as a mediator
of resistance to tamoxifen (9;61) and neoadjuvant studies suggest that in fact HER2
positive cancers may derive greater benefit from AIs than tamoxifen (62). However,
a recent analysis of the BIG-I-98 trial, whilst suggesting that HER2 was indeed
predictive of early relapse, failed to substantiate the interaction between HER2 and
treatment with AIs (63). Critically, the authors correctly note that despite the large
sample size of this study (7707 samples) the low rate of HER2 positivity (ca 5%) and
low event rate to date (3.7%) in this low risk ER-positive population provided
insufficient power to address the question of interactions between HER2 status and
treatment modality. Therefore, in this respect, this study is unable to provide a
definitive answer and further analysis or meta-analysis of the major adjuvant AI
trials is awaited.
A second example relates to the potential interaction between HER2 and or
topoisomerase Ila and response to anthracyclines, as previously mentioned. Several
conflicting studies have been published with no clear evidence to suggest whether
the interaction between response and biomarkers is attributable to topoisomerase Ila
or HER2 (reviewed in (64)). Two conflicting reports relating to the BCIRG 006 trial
were presented at the San Antonio Breast Cancer Symposium in 2005 and 2006. In
the first report, based on the interim analysis of almost 60% of cases recruited to the
BCRIG006 trial, a potential interaction was suggested between topoisomerase Ila
and benefit from anthracycline treatment (65). The second analysis, based on
analysis of over 90% of cases, and with increased follow up, failed to identify any
interaction (8). Two potential explanations exist for this difference, observed within
the same study population and reported by the same group. Firstly that the first
interim analysis was, in some way, biased by the inclusion of only a small proportion
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of patients within the total trial population. Secondly, that in fact the interaction
between biomarkers and treatment outcome is in some way time dependent. This is
discussed in greater detail in Chapter 2 Further analysis of the BCIRG006 and other
datasets will be required to investigate these possibilities.
These examples, however, serve to underline the fact that biomarker analysis is a
complex field and one where simplistic answers are hard to come by. For appropriate
studies to be designed and correctly interpreted statistical approaches no less
rigorous, and potentially more complex, than those employed for the analysis of
primary endpoints of response must be employed. Treatment interactions with
biomarkers, where treatment response may differ between biomarker positive and
negative cases, require multivariate analyses which increase the required sample size.
Agreed analytical procedures, which address the potential for interactions between
biomarkers and treatments and the potential for such interactions to change over time
will need to be determined for future biomarker analyses. Finally, caution must be
applied to inappropriately powered studies and, where biomarkers may select small
subgroups of cancers, meta-analysis of compatible trials may be required in order to
provide definitive answers to some questions.
1.6 Conclusions
In this chapter we have highlighted some of the hurdles which have to be jumped
before predictive biomarkers can be considered for clinical practice, with regards to
current approaches to tissue biomarking in breast cancer and candidate biomarkers
which are likely to be tested in the clinical arena in the relatively near future. Even
biomarkers such as Tlla, which have been recognised as potential markers for
several years and tested within large Phase II trials, are courting controversy. We
have shown how the 'biomarker journey', from bench to bedside, should be
underpinned by sound biological hypotheses. Predictive biomarker development will
need to change from 'survival of the fittest' (ie value based on publication
frequency), to a structured, multi-tiered approach, including the use of preclinical
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models, neoadjuvant clinical models, properly designed retrospective studies, and
validation within prospective clinical trials. The development of robust and accurate
diagnostic assays should precede, not follow, the identification of a potential clinical
role for biomarkers.
Predictive marker development requires the coordinated effort of multiple academic
institutions and industry to cover all the aspects of development. It takes many years,
large investments, and the risk for failure is high because of the nature of drug
development. That may be the reason why so few new markers have been introduced
in recent years despite major research, development efforts and new techniques.
However, there is cause for optimism for the future, provided rigorous scientific
procedures are followed in biomarker analyses. Some new advances in reducing risk








In Chapter 1 we discussed the current state of biomarker development in breast
cancer, which has been driven largely by the will of the oncology and translational
science community. Arguably, there has not been consistent and well-funded input
from pathology into this interface between biomarker discovery and oncology. In this
chapter we discuss the role that modern molecular pathology and systems biology
might play in overcoming some of the problems which were discussed, such as
effective preclinical testing and a lack of systematic interrogation of the underlying
biology, using cutting edge approaches and techniques. The wealth of morphological,
histological, and molecular data from human cancers available to pathologists means
that pathology is poised to become a truly quantitative systems science. By
measuring morphological parameters such as tumour stage and grade, and by
measuring molecular biomarkers such as hormone receptor status, pathologists have
sometimes accurately predicted what will happen to a patient's tumour. While 'omic'
technologies have seemingly improved prognostication and prediction, some
molecular 'signatures' are not useful in clinical practice because of the failure to
independently validate these approaches particularly when applied outside the setting
of a clinical trial, and because many tests have a low positive predictive value. Many
associations between gene 'signatures' and clinical response are correlative rather
than mechanistic and are poor predictors of how cellular biochemical networks will
behave in perturbed, diseased cells. Using systems biology, the dynamics of
reactions in cells and the behaviour between cells can be integrated into models of
cancer. The challenge is how to integrate multiple data from the clinic into tractable
models using mathematical models and systems biology, and how to make the
resultant model sufficiently robust to be of practical use. In this chapter we also
discuss the difficulties in using mathematics to model cancer, and review some
approaches in systems biology and experimental pathology which may be used to see




New mathematical models exploit what is known about signalling networks and
therapeutic mechanisms to produce a dynamic system, which can be personalized
and used to simulate the natural history of a tumour and responses to therapy. In
addition to being a practical tool to aid patient management, it is also a powerful
hypothesis-generator, exploiting what is known about molecular tumour pathology
and what is not known and worthy of further investigation.
Kinetic modelling of complex biological systems, however, is still perceived
as esoteric and not clinically applicable because there are very few successful
examples of when such modelling has changed practice (66). One notable exception
is modelling of ion-channels in the heart which has helped explain the previously ill-
defined action of the drug ranolazine (67-69). These modelling data were
subsequently used within an FDA submission as supportive evidence for mode of
action ((70) and http://www.fda.gov/bbs/topics/news/2006/NEW013Q6.html). In
oncology, systems biology has not yet made the same impact, but with the increased
use of therapies targeted against the products of cellular oncogenes, the practical and
clinical implications of more in-depth understanding of deregulated signalling
pathways is starting to impact on clinical practice. For example, activating mutations
in the oncogenic PIK3CA and inactivation of the tumour suppressor gene PTEN are
known to regulate phosphotidylinositol 3-kinase signalling and cell proliferation and
survival pathways, which have a role in resistance to anti-HER2 therapies in breast
cancer (as already discussed in Chapter 1 and (71;72)). Recent advances in
histopathology, molecular pathology, and computational biology make it feasible to
test the hypothesis that systems biology can predict responses to cancer therapy in
real patients using data from existing clinical trials. A dynamical systems approach to
integrating multifaceted and complex data from cancer cells and tissues is more than
simply consideration of histological pattern recognition, grade, stage, and genetics,
proteomics, and molecular pathology data. Here we suggest ways forward using
mathematical and biological models, clinical tissue samples, and methods of data
generation, which have allowed this area to evolve, and we also discuss some of the
challenges that remain. The molecular basis of breast cancer is particularly well
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understood and is therefore data-rich compared to other solid-organ tumours.
Predictive pathology tests (such as ER and HER2 immunohistochemistry) are used
routinely in the clinic in breast cancer, but there is room for improvement. It is
therefore a good disease on which to discuss some of the issues surrounding
mathematical modelling and response prediction.
2.3 Making predictions from histopathological snapshots
Cancer is a complex, dynamic disease characterized by the ability to become
autonomous in growth, evade death, sustain angiogenesis, invade surrounding
tissues, and to metastasize (73). Currently, pathologists generate data from a single
pathological snapshot, which acts as a surrogate of the intrinsic biology of the
tumour (Figure 2.1), and forms part of the clinical record from which treatment
decisions are made. This approach is remarkably powerful and has stood the test of
time for prognostication; however, it does not meet the challenge of predicting
individual responses to treatment. The most common classification of tumour stage is
the TNM classification, which is based on tumour size, and the presence of nodal or
distant metastases (74). The tumour stage gives an estimation of the amount of time,
or degree of tumour progression, between tumour initiation and resection. The longer
the time period between tumour initiation and resection, the greater the chance that
the tumour will have undergone clonal evolution and acquired a set of unfavourable
characteristics, such as greater size, ability to invade lymphatics or blood vessels, or
metastasize to distant sites. In breast cancer, the grade of the tumour is a semi¬
quantitative composite of mitotic activity, nuclear pleomorphism, and tubule
formation (75), which is an indication of the intrinsic biology of the tumour. A high-
grade breast tumour with a pushing border, prominent lymphocytic infiltrate, central
necrosis, metaplastic elements, and brisk apoptotic rate is likely to belong to the
'basal-like' group of breast cancers (76;77), although it is unclear whether this is
really a distinct histological or biological group (78). Clinically, these tumours are
associated with a poor prognosis and comprise 20% of the total invasive ductal
carcinomas. Data generation from tissue has been further refined by advances in
molecular classification of cancers by whole-genome expression and analyses of
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gene amplification or gene loss (79;80), and pathologists can make even more
detailed assessment of intrinsic pathway biology based on morphological features
alone. Tumours of the basal group of breast cancers are likely to express low or no
levels of ER, are HER2 negative, but have a high incidence of EGFR protein
overexpression or amplification at the genomic level (77). These tumours are likely
to harbour overexpression or mutation of p53 and therefore have abnormal cell
survival responses (77). If the tumour has occurred in a patient younger than 50, the
patient is likely to harbour a germ line mutation in BRCAI, and she and her family
should undergo genetic counselling and testing (81). The tumour is likely to respond
to treatment with platinum-based or taxane chemotherapy (82;83), and would be a










+ DRUG THERAPY = PREDICTION
Figure 2.1: The current state of pathology. Therapeutic outcome is inferred from
stage (macroscopic data) and grade (microscopic data), which are surrogates of time
passed and intrinsic biology. Systems pathology, applied to oncology,
mathematically describes tumour behaviour after diagnosis (dashed line), allowing
simulation of the effects of disease modifiers (ie drugs) on outcome or, in the reverse
causal direction, what combination of drugs in a particular tumour are needed to





Therefore, from static measurements alone pathologists are good at
estimating dynamic processes such as prognosis through the integration of grade and
stage, and this is rarely surpassed in multivariate analysis by ancillary methods such
as immunohistochemistry for tissue biomarkers or flow cytometry for DNA content
(84). In a limited numbers of cases, such as in basal-like carcinomas with
characteristic morphological features, the static morphological snapshot broadly
defines the activation status of up to five pathways implicated in carcinogenesis (i.e.
EGFR, ER, HER2, p53, and BRCA1). It has been proposed that the 80 or so
mutations found in solid cancers can be reduced to a limited number of abnormal
pathways (85). Therefore, traditional morphological pathology can already
comprehensively define the molecular pathology of the tumour in these cases, and
this information can be used to plan the management of patients, and be exploited
for targeted and combinatorial therapy (85;86).
2.4 Improving predictions from molecular markers
With the advent of 'targeted' therapies that recognize and target cellular oncogenes
such as trastuzumab (Herceptin) that targets the HER2 receptor, there is a need for
accurate characterization of the underlying oncogenic signalling pathways (72). We
need to know not only the structure of these pathways, but also how manipulation of
a part by a drug might affect the dynamics at the cellular and tumour level. To date,
this approach has relied on static pathological measurements. Morphology alone is
powerful, but reflects pathway biology only in a very limited sense, due to the
remarkable heterogeneity of solid tumours, lack of distinct clinicopathological
entities, and lack of comprehensive molecular classification of the majority of
diseases. Although traditional histopathology has enabled rigorous validation of
histological prognostic features to clinical endpoints such as relapse and survival, the
management of patients with cancer based on prediction of how the patient will




As a result of the complexity of tumour biology, patients tend to be over-
treated, on the premise that offering a therapy with a small chance of success is still
preferable to offering no treatment at all. Thus, 60% of patients with breast cancer
unnecessarily receive endocrine therapies (87), and the benefit derived from
trastuzumab is only seen in 30-40% of patients who receive it (88). As discussed in
Chapter 1, with the exception of ER and HER2, no other predictive tissue biomarkers
have been widely adopted in oncology, despite the plethora of literature that indicate
new predictive markers for assessing responses to agents (84). We have already
discussed, as have several articles, the reasons for this situation (84;89), but
essentially the current approach to translational research by the analysis of candidate
biomarkers, even within large trials, requires re-evaluation. The emerging evidence
indicates that failure to recognize dynamic properties of signalling can result in
costly mistakes. For example, loss of feedback inhibition in tumours treated with
mammalian target of rapamycin (mTOR) inhibitors results in induction of AKT
signalling, and may be responsible for the disappointing efficacy of mTOR
antagonists in the clinic (90). Negative feedback signalling mechanisms are likely to
contribute to the poor efficacy of agents when studied in phase II and phase III
cancer trials and to the high rate of attrition of drugs (approximately 30% due to
efficacy), which is both time consuming and expensive (91). Empirical testing of
every possible agent or combination of agents in the preclinical or clinical setting
would be prohibitively expensive and impractical.
Kinetic mathematical models, therefore, offer the potential to relate
molecular-level knowledge to outcome at the cellular and tumour level. Essentially
models provide the opportunity to perform trials in silico (that is via computer
simulations), not necessarily to provide a definitive answer but to contribute to a
body of evidence in order to make informed decisions about predicted efficacy.
Utilizing dynamic models as predictive tools, therefore, holds promise for reducing
treatment failures. Nonetheless, progress in the development of mathematical models
suitable for implementing pathology has been slow, as discussed below.
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2.5 Why has it been difficult to mathematically model cancer?
We have reviewed the current approaches to modelling cancer elsewhere (92) and
have identified both limitations and potential opportunities. With particular regard to
pathology, we can identify a number of challenges facing such approaches that must
be overcome for the oncology field to progress.
2.5.1 Network complexity
Cancer is a heterogeneous and complex set of diseases, resulting from the
accumulation of multiple genetic defects resulting in aberrant pathway activation and
disordered growth and survival (73;93;94). At the cellular level, the network of
interactions between the various signalling and regulatory pathways governs cell
behaviour. In general, the interactions between the components of the cell network
are non-linear. This means that small uncertainties in relationships between pathways
and the defining parameters of their interactions leads to disproportionate errors in
predicted dynamics (95). Given that we will never know the exact details of the
network, and that these will vary between patients and at different times in the
progression of the disease, it seems improbable that precise definition of metabolic
and signalling pathways in cancer is either possible and may not even be desirable.
2.5.2 Cancer measurements are static, not dynamic
Based on grading and staging, the rate of proliferation, and the invasiveness of
tumours are major determinants of prognosis (74). The behaviour of cancer is most
often characterized pathologically in terms of data collected at a single time point
(e.g. from a treatment-naive diagnostic biopsy or resection specimen) or at relatively
few time points in in vitro cell-line studies. These data are considered along with
other data such as imaging and clinical staging. In essence, clinicians infer




The phenotype of a tumour is not governed only by the epithelial component but also
but the tumour environment, that is other cells in contact, the mesenchyme, and
inflammatory infiltrate, because these components determine the net inputs to the
cell, which includes ligands, cell-cell adhesion molecules, metabolites, oxygen, and
drugs. It is important to know how to characterize and quantify the spatial
heterogeneity at a given time to inform our understanding of the dynamics. This
includes the collection and interpretation of measurements of both the intracellular
and extracellular environment. On a finer scale, the intracellular regulatory network
is imbedded in a complex spatial context within the cell (96). Many key processes
occur on surfaces or across membranes and this spatial compartmentalization within
cells has a profound impact on the dynamics of signalling within cells and therefore
their response to the environment (96). Relatively little information is available on
the spatial organization of key proteins within cells, although recent imaging
techniques offer the potential of high-resolution measurements of the spatio-temporal
dynamics of large numbers of proteins (97).
2.5.4 Uncertainty and incomplete knowledge
Perhaps the incomplete knowledge of the underlying biology contributes to our lack
of understanding of complex biological systems. There is no a priori reason why
system behaviour should not be highly sensitive to the specific functions of the
signalling network. Indeed the efficacy of targeted therapies result from such
sensitivities (98;99), and many serious consequences and adverse effects can arise
from relatively few, though coordinated, point mutations in key target genes involved
in signalling pathways (85). A combination of the strength of the interactions, the
complexity of the networks and the dynamics of the systems, means that a full
characterization of the interaction network implicated in cancer could require a
prohibitive quantity of data.
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2.5.5 Combining qualitative and quantitative data
There are a large amount of data and knowledge relating to cancer, but much of it is
difficult to integrate for mathematical modelling (for instance sequencing data, copy
number gains and losses from array comparative genomic hybridization, high-
throughput transcriptional data, quantitative PCR data, biochemical data from in
vitro and cell based assays, animal models etc), because it is not quantitative,
generated in different experimental models, related to a single timepoint, or generates
inconclusive results. Thus a range of bioinformatics approaches and new data
standards are being developed to address this problem, particularly with respect to
high-throughput data and standards within systems biology (100; 101). Much of our
knowledge concerning biological systems is qualitative but later we propose ways to
move pathology towards more-accurate quantification of molecules and their
dynamic interactions in tissues.
2.5.6 Physiology versus pathology
Computational systems biology has allowed us to test our understanding of the
dynamic behaviour of a few well-characterized pathways using computational
models to predict their behaviour (102-108). These models have proven to be
extremely useful in helping us to understand the behaviour of quite complicated
intracellular signalling pathways, for instance the canonical MAPK and PI3K growth
and survival pathways (103; 106; 109), and changes in the cell cycle (102), in
response to physiological stimuli such as growth factors (102-105; 110). However,
such models have not been so helpful for understanding therapeutic interventions.
'Bottom-up' approaches (in the context of systems biology) are when cell signalling
pathways are reconstructed from the literature, whereas 'top-down' approaches are
where network structure is constructed from high-throughput, high-density datasets
such as transcriptional profiles. Bottom-up approaches have contributed extensively
to the foundations of systems biology by modelling physiological pathways and
describing systems behaviour such as emergent properties (e.g. thresholds,
oscillations and signal duration) (95). However, bottom-up approaches have focused
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on physiological rather than pathological systems (such as EGFR signalling and
PI3K signalling), which are simpler. Such approaches frequently fail to include
important oncogene and tumour suppressor nodes, which are known to be
fundamental to breast carcinogenesis and proven resistance proteins (such as HER2,
PTEN, and SRC in PI3K and MAPK signalling models). Currently, no dynamical
models incorporate ER signalling as a core module, which is clearly essential to
understanding anti-estrogen responses in breast and ovarian cancer.
2.6 Proposed solutions
A full description of mathematical techniques for kinetic modelling employed in
cancer is beyond the scope of this review, and more-comprehensive descriptions
have been published elsewhere (95; 110; 111). As a means of illustrating a vision for
systems pathology, we outline broad illustrative mathematical techniques in dynamic
modelling, which would allow pathology to be embedded in a systems framework,
either indirectly by contributing to decision-making in translational medicine, or by
the direct use of molecular pathology data in mathematical models. Initially such
models might be used along with other forms of evidence, such as preclinical testing
and data from early phase trials in order to obtain rationally selected biomarkers or to
choose or reject certain drug combinations over others. In time, computational
modelling would run in parallel with ancillary tests and form part of the pathology
report and decision-making process. Since no single systems biology approach is
universally appropriate (108), we suggest that there are advantages for progressing
complementary hypothesis-driven and data-driven methodologies. Each approach
offers advantages over the other, but each has their own limitations.
2.6.1 Hypothesis-driven approaches
Hypothesis-driven approaches that are relevant to the study of the dynamics of cell
networks include those where the network is prescribed a priori, such as
mechanistic, deterministic ordinary differential equation-based mathematic models
(e.g. those describing EGFR signalling) (103; 105). The intricacies of the interaction
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network is often the subject of investigation in itself, and so any prescribed network
should be taken as a working hypothesis. Except in a few cases, the quantitative
details of the interactions are unknown and so it is necessary to hypothesise relevant
forms of the equations governing the interactions and estimate the values of the
associated parameters. A major challenge of this approach is that the level of detail
demands knowledge of a large number of parameters to fully characterise the
dynamics of all the interactions. For this reason, hypothesis-driven approaches have
generally only been applied to relatively small networks where comparatively large
amounts of quantitative data are available (95). However, as many new therapies in
preclinical or early phase trials are targeted against well-characterised pathways (e.g.
mTOR inhibitors, PI3K inhibitors, RTK inhibitors) for which models exist but which
are missing key oncogene or tumour suppressor nodes (e.g. PTEN in EGFR
signalling models, or mTOR module), it would be relatively straightforward to
extend these models to investigate resistance factors, or interrogate network
behaviour. In this way, unwanted signalling feedback from mTOR to pAKT would
be determined before clinical testing (90), and candidate sensitivity and resistance
biomarkers may be prospectively selected with a greater level of evidence and
confidence, such as PTEN in trastuzumab resistance (see Chapter 6 and (51 ;71)).
Some have argued that hypothesis-driven approaches have no rational limit to
the level of detail needed, and that the demand for quantitative dynamic data is
unattainable, making this approach unlikely to succeed. In other words there is
simply no end to the requirement for data. There are data indicating that as
complexity grows, the behaviour of the network becomes insensitive to the details of
many of the interactions (112). This outcome would indicate a logical limit to the
level of detail required, beyond which additional complexity does not contribute
significantly to the predicted dynamic behaviour of cell systems. If this is true, then
we need not be limited to 'small' ordinary differential equation-based mathematical
models, which are descriptions of relatively small parts of the regulatory network of
the cell. Instead, we can build larger ordinary differential equation-based
mathematical descriptions that are sufficiently comprehensive to link combinatorial
approaches spanning multiple pathways and pathology (113). Thus, systems
pathology can maintain a pragmatic approach to the complexity of data generation
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guided by its ultimate usefulness for diagnosis, prognosis, and prediction of response
to therapy.
We often want to be able to ask questions in the reverse-causal direction such
as "how do we need to change the system to realize this (qualitative) result?" As an
example, a systems model for breast cancer can be developed using data obtained
from tissue measurements obtained from a given patient (e.g. quantitative
measurements of HER2 amplification status, ER and PTEN expression levels). For a
given set of potential drugs, we can use the model to predict combinations and doses
of the different drugs that return the cell to a normal, non-proliferating state (Figure
2.2; reproduced with permission of Robert Clyde, University of Abertay, Dundee).
An advantage of this approach would be to use the model to predict the
consequences of each of the drug combinations found to be consistent with the
desired outcome on cancer cells, and predict their consequences for healthy cells.
Hence, the model could be used to predict drug regimens tailored to individual
patients that are most likely to have a good outcome with minimal toxicity. Although
this approach would require additional compartments in the model to deal with the
relevant pharmacokinetics, the result can be achieved by using the model for
different combinations of drugs and applying optimisation approaches (e.g. genetic
algorithms) to converge on combinations that are consistent with the desired
dynamical outcome, such as a pro-apoptotic response in cancer cells that harbour
oncogenic mutations, and no response in normal tissues. It is likely that as this kind
of model becomes more quantitative and our knowledge increases, so too will the
need for quantitative, quality-assured molecular pathology data.
The interaction networks implicated in cancer not only include those within
cells (e.g. EGFR or PI3K signalling networks), but between cells and their
environment, and other regulatory networks including the endocrine and immune
systems. Any systems approach must be consistent with incorporating higher levels
of organisation as required by the particular application. The simplest way to do this
is to abstract the system into relevant functional modules that interact with each
other. Examples include the cell, the cell environment, the vascular system, and the
endocrine network, similar to that already described for the heart (68). In this way
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heterogeneity at the tumour level can be accommodated by representing a number of
different (evolvable) cell types interacting via a dynamic environment. This model
approach is only possible if the associated interactions can be characterized
sufficiently accurately to allow reliable prediction. Techniques exist for deriving the



















Figure 2.2: Simulation of molecular activity in ER+Her2+ breast cancer using a
'large' (>200 species) ordinary differential based model. Lines represent
concentrations of cell cycle proteins in the cell over time. a. A 'normal' breast
epithelial cell has very little cell cycle progression under resting conditions, b. The
same cell, when harbouring commonly found aberrations in endocrine pathways,
oncogenes, and tumour suppressor genes (ER, HER2 and PTEN) shows ordered cell
cycle progression and proliferation, c. The same cancer cell after treatment with a
combinatorial drug regimen consisting of tamoxifen, an mTOR inhibitor, and
trastuzumab identified by a search algorithm. There is almost complete inhibition of
proliferation under these conditions, which would be expected to translate into
clinical benefit.
Where these approaches employ genetic algorithms to evolve or define the
parameter, the target behaviour of the model can be expressed both quantitatively




Important examples of data-driven approaches are general power-law formalisms (a
set of mathematical tools for the approximation, modelling, numerical simulation and
analysis of nonlinear systems) including Biochemical Systems Theory (115) and
Metabolic Control Analysis. Power-law formalisms have been employed in the study
of biological networks for more than 30 years, although Metabolic Control Analysis
has only recently been applied in the study of cancer (116). Data-driven approaches,
including power-law formalisms, are essentially local approximations of the cell and
its microenvironment. This means that any resulting analyses are only valid when the
cells are infinitesimally close to their state at the time of measurement. The
Biochemical Systems Theory is based on an underlying S-system (which is a
mathematical representation of non-linear systems, based-on power laws) approach
that explicitly represents the dynamics of the network in terms of differential
equations that describe the rate of change of variables such as protein concentrations
or gene-expression levels (117). The equations characterise the rate of change of the
variables in terms of the interaction between components of the system as products
of power-laws of the concentrations (or expression levels) of these components. It
can be shown that any kind of interaction can be approximated by this form, at least
locally.
Using an S-system approach, one can derive an interaction network for a
given set of measured variables by deriving the values for the power-law exponent
by fitting the equations to time series data (any form of data in which kinetics are
described by making a series of measurements over time). Where this fit returns a
value of zero, one can infer that the variable in question is independent of that
component. By noting only those non-zero exponents for each variable in the system,
one can build up the network of interactions between them. As shown in Figure 2.3,
this network can be visualized to indicate those links that most sensitively affect the
rate of change of connected components. In this sense, the derived network can be
used to identify components as potential targets for changing the dynamical state,
such as a new drug target or tumour-suppressor nodes. The prediction is valid
provided the system is not changed too much from the dynamical state in which the
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original measurements were made or where combination therapies are being
considered. To our knowledge, the S-system approach has not been applied to the
study of cancer, because currently the use has been restricted to a relatively limited
number of theoreticians. However, it is beginning to be used in relevant areas of
biology such as the analysis of experimentally-derived time courses of cDNA gene
expression array data, albeit in yeast (118). This is promising since it is proof of
principle that indeed the technique may be used in gene expression data generated
from cancer specimens, such as those taken at different timepoints in a neoadjuvant
trial.
Figure 2.3: Network interactions in cancer, derived from quantitative protein
time-series data in vitro using the S-systems Biochemical Systems Theory
approach. In response to extracellular ligand, a network diagram is constructed
which accurately reconstructs network biology (receptor dimerisation, positive and
negative feedback loops). The tumor suppressor role of the tumor suppressor protein
(centre) is readily appreciated through multiple inhibitory links to cell growth
proteins, and suggests that loss of this key 'node' will result in uncontrolled
proliferation. For new networks this leads to new hypotheses, or druggable targets.
Blue lines = activation/phosphorylation, grey lines = inhibition/dephosphorylation,
black lines = autophosphorylation, numbers = strength of interaction. Reproduced
with the permission of Michael Idowu, University of Abertay, Dundee.
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An interesting and recent alternative data-driven approach that can be used
when qualitative and/or imprecise measures are present exploits fuzzy logic (119), a
mathematical term used to describe decisions or biological readouts which have a
continuous range between 0 and 1, that is they are imprecise but within boundaries,
in contrast to binary logic, when the decision is discrete, either 0 or 1. The state (eg
of a probe measuring gene expression on a cDNA microarray) may be imprecisely
but qualitatively defined and the rules mapping the state to a future
imprecise/qualitative state are based on a set of probability-like functions. The
limitations of the approach are similar to those for the other data-driven approaches
described above, and their application to large, highly interconnected, networks can
result in an unmanageable volume of data required to calibrate the models.
2.7 Data requirements
Although the past few years has seen massive increases in the amount of data
generated from biological samples, particularly in the form of gene-expression
microarrays, embedding pathology and tissue-based analysis within the systems
framework may offer new opportunities for prediction in patients with cancer. If
powerful systems tools are to be adopted by the clinical community, it is critical that
those individuals involved in clinical trials (particularly oncologists) are aware of
these challenges, since they must be specifically addressed in the trial design and
planning stages. By doing so, the quality and quantity of pharmacodynamic and
pharmacokinetic data may be vastly improved.
2.7.1 Achieving spatial resolution
In tissues, two spatial levels must be specifically resolved; tissue compartments or
variability within compartments (i.e. epithelial, stromal, inflammatory component,
vascular, and interstitial) and cellular compartments (e.g. immediate extracellular
environment, membrane, cytoplasmic, nuclear and organelles). We use two strategies
to combine compartment-specific analysis with high-throughput molecular analysis;
microdissection and in situ protein quantification. Microdissection is becoming a
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standard strategy in gene-expression microarray (120) and genomic hybridization
protocols (121) in order to enrich for epithelial-cell populations, either to overcome
the inherent limitations of sensitivity of the assay (as in array CGH) or in order to
infer compartment-specific biology (as in the case of gene expression) (120; 121).
Microdissection might mean a relatively crude dissection of the epithelial area of a
tumour by hand under a dissecting microscope, or alternatively the use of laser
capture/catapult microdissection techniques in order to obtain populations of pure
cells (122). The latter approach may be more suited for systems biology because the
methodology can also be extended to separate any tissue compartment (e.g. blood
vessels, stroma), and also morphologically heterogeneous elements within the
epithelial areas of tumours, which have differential gene and protein expression
signatures and therefore potentially different responses to therapy. The second
method we are using is in situ protein quantification on automated image analysis
platforms for total and phosphorylated (usually active) states of proteins within
signalling pathways of interest (see Chapter 4, 5 and 6 and Figure 2.4) (123). These
methods multiplex antibodies against particular compartments (e.g. epithelial) with
one or more targets of interest, so that compartment-specific protein expression can
be quantified. The advantage of this technique over microdissection methods is the
ability to discriminate protein expression levels at compartmental and subcellular
levels. However, disadvantages include the limited number of targets that can be
measured from a single section (which is governed by the number of filters (usually
up to five) on the fluorescence microscope), availability of high-quality specific
antibodies, tissue auto-fluorescence, and difficulties with absolute quantification. In
addition, most histopathology labs use colorimetric techniques rather than
immunofluorescence for biomarker quantification, and do not have access to this
cutting-edge technology. We have therefore also used immunohistochemistry-based
quantification to measure ER in tissue sections from breast cancers, which may be
more readily applicable to clinical pathology laboratories in the near future (see
Chapter 3). While most in situ methods are limited to protein techniques, all
macromolecules may be extracted from microdissected tissues, including RNA,
microRNA, DNA, and protein. Each macromolecule is amenable to high throughput
array-based technologies and, in the case of protein, the tantalizing prospect of
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reliable clinical mass-spectrometry proteomics (124) can offer quantitative







Figure 2.4: New analytical tools and biological models for systems biology. (A)
The AQUA image analysis system uses proprietary image analysis software (RESA)
and algorithms (PLACE) to quantify protein expression in tissue compartments,
which may be used in mathematical models (reproduced with permission from
Marisa Dolled-Filhart, Yale School of Medicine). (B) Contracted collagen matrix
model for investigating epithelial/stromal interactions in vitro. Changes in phenotype
may be modelled under different epithelial (middle and lower panes) and stromal
conditions and over time (reproduced with permission from Elad Katz, Edinburgh
Breakthrough Research Unit).
34
2.7.2 Achieving temporal resolution
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Although increasing temporal resolution seems straightforward for in vitro-based
experiments it is more difficult within the clinical setting. There are a range of
biological models available for analyzing complex biological systems. Nonetheless,
even the simplest in vitro models require reconsideration of design in order to
generate data of sufficient quality to populate mathematical models. While it is
relatively trivial to increase data points in an experiment examining pathway
responses to targeted therapy in vitro, it is only recently that downstream assays are
sufficiently 'high-throughput' to generate robust, quantitative data of sufficient
quality and quantity to be used to populate mathematical models. This situation is
readily appreciated for protein assays; for example, if more than 10-15 samples are
assessed by western blotting it becomes increasingly difficult to maintain accuracy,
reproducibility, and (more importantly) quantification both within and between blots.
If a simple time course with 10 time points for 10 pathway biomarkers is assessed,
inclusion of appropriate total protein controls would produce 200 data points, which
highlights the issue of non-scalability of data. Although robotics can help to meet the
demands of high-performance throughput, new techniques need to be considered to
meet the data-rich demands of systems approaches.
Since many of the components assessed within mathematical models are
proteins and their activated forms, newer protein assays may be used in order to
address the problems outlined above. Reverse-phase protein arrays (RPPA) are high-
throughput, high-density protein arrays in which protein lysates from in vitro or in
vivo biological samples are immobilised as spots on nitrocellulose-coated glass slides
and protein targets are detected with specific antibodies, similar to
immunohistochemistry or immunofluorescence (125). In this way, hundreds to
thousands of lysates (including technical and biological replicates) can be assayed
under the same conditions on a single slide. As only picoliter quantities are spotted
on each spot, tens to hundreds of identical slides may be produced for multiple target
analysis from a single cellular or tissue lysate, particularly if robotic spotting is used.
In addition, since each lysate is spotted as a dilution series, the signal detected can
always be guaranteed to be in the linear range of detection (that is while signal
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intensity is still unsaturated), which is rarely the case for western blotting, and if
recombinant peptide or protein controls are spotted on the same slide, accurate
quantification is possible. As well as facilitating high throughput protein analysis in
vitro, the small amount of lysate required and the high number of assays that can be
performed make this a useful technique for assessing clinical material. This means
that large models, requiring tens to hundreds of biological measurements (e.g. the
ordinary differential equation-based approach) may be populated with ease. We have
used this technology in order to populate a new mathematical model of PI3K
signalling in Chapter 6.
The second most important challenge to achieving sufficient temporal
resolution for systems approaches is selection of appropriate in vitro or in vivo
models. While transgenic mice offer the attraction of stable genetic perturbations that
can be applied to computational models, the long generation times and high numbers
of time points required do not lend themselves to the iterative nature of systems
biology ie the need to refine the model on the basis of re-experimentation, in order to
improve it. Nevertheless, if coupled with live imaging techniques, such as the
relatively new technique of intravital microscopy, which has been used to image
tumour cell invasion in real-time (126), these animal models may become attractive
models for detailed pharmacodynamic studies. We have used a combination of 3-
dimensional in vitro primary and human adenocarcinoma cell line cultures on
contracted collagen matrices (127) and cell line xenografts to model the
pharmacodynamics of targeted therapies (Figure 2.4B, reproduced with the
permission of Elad Katz, Edinburgh Breakthrough Research Unit). Three-
dimensional culture simplifies the tumour context but offers flexible analysis of
epithelial and stromal compartments, where both compartments may be genetically
manipulated and subjected to both destructive and non-destructive temporal analysis,
such as by reverse-phase protein arrays and immunofluorescence. Primary and cell-
line xenografts capture the complexity of whole tissues but what makes these models
ideal for high-throughput, spatially resolved analyses is their ability to assess
tumours from multiple time points, and the availability of abundant tissue for fresh
frozen and formalin-fixed paraffin-embedded analysis. In addition, cell lines are
readily manipulated in vitro for knockdown or overexpression of specific targets with
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small hairpin RNA and stable transfection of genetic constructs, respectively, and are
then ready for re-implantation and re-testing of the system with specific
perturbations. These models are an important intermediate step in validating
computational models before they are sufficiently reliable to be used in clinical
decision-making.
The real challenge lies with achieving sufficient temporal resolution using
real human disease as the model. Nevertheless, there is now extensive experience in
gathering tissue and biological samples from three time points in the neoadjuvant
setting in individual patients with breast cancer, such that limited pharmacodynamic
studies may be performed. In this model, patients are given endocrine or
chemotherapy for 3 months prior to definitive resection and samples taken at
diagnosis, 2 weeks, and 3 months at the time of resection (128). If basic pathological
endpoints such as proliferation (immunohistochemistry analysis of Ki67 expression
levels) are measured, then the proliferation index at 2 weeks (but not at diagnosis) is
predictive of long-term survival in response to aromatase inhibitor therapy (129; 130).
Breast cancer is amenable to this type of temporal intervention, since there is the
added benefit that tumour shrinkage in the neoadjuvant setting can result in the use
breast-conserving surgery rather than mastectomy. Nevertheless, other cancers may
also be amenable to multiple sampling, such as ovarian tumours treated with intra¬
peritoneal chemotherapy (131), or colorectal tumours treated with pre-operative
radiotherapy (132), which may be achieved with minimal discomfort or
inconvenience to the patient. By exploiting carefully selected human models, we can
begin to determine the true nature of the dynamics of tumour responses and move
away from inferred biology from static biomarker analysis. In the short term
gathering high quality, temporal data from real clinical material is essential to
populate and validate computational models. In time, such mathematical models are




The increasing availability of high throughput molecular techniques offers an
unprecedented opportunity to complement existing histopathology approaches to
better characterize tumours for predicting prognosis and improving treatment of
cancer. At the same time, our understanding of the molecular basis of tumours is
improving to the extent that large parts of the regulatory networks are now well
characterized. For targeted therapies that modify the network at the single pathway
level, the challenge is to link tissue data to modifications at the molecular level that
will improve outcomes. This chapter highlights why measurements at a single time
point do not encapsulate the required information, and points to the need for
measures that characterize the dynamical state of the underlying pathobiology. The
resulting complexity of the description necessitates a mathematical modelling
approach, and we identify potential methodologies that may be suitable, along with
the necessary experimental measures that are required. Pathology as a recognised
specialty is at a point where it may be possible to integrate quantitative methods and
predictive tools to aid in the diagnosis, prognostication, and prediction of response in
patients with cancer. The consensual platform that is provided by the explicit
expression of understanding in a systems model offers the possibility for a more-
rational approach to data collection and interpretation. Whilst we find that larger,
more-comprehensive models for the regulatory network are required, this need not
translate into a demand for larger volumes of data. Indeed, a major benefit of such a
platform is in identifying where data is critical and where it is not, and where high
temporal resolution is required and where it is not. Perhaps of most importance is a
platform based on explicit molecular-level modelling, properly integrated with
appropriate pathological data, could help to ensure that future research in this area








In the preceding chapters we have discussed the need for validation of appropriate
biomarkers in sufficiently powered clinical trials, and the need for accurate
quantification. In this chapter, we bring these themes together and investigate the use
of semi-automated biomarker analysis in a trial setting. In doing so, we validate an
immunohistochemistry-based image analysis system, which may be more readily
applied to pathological practice than immunofluorescence-based systems. We show
this in the setting of the TEAM trial, which is powered to investigate differences in
responses to endocrine therapies according to tissue biomarker status. Central to
these responses is the expression of ER and PR, which are known to influence
responses to endocrine therapy (133; 134). We therefore sought to establish whether
ER and PR could be quantitatively measured using image analysis, so that
quantitative expression could be assessed within the wider trial.
The Tamoxifen versus Exemestane Adjuvant Multinational (TEAM) trial is an open-
label, multinational, phase III trial which recruited 9746 postmenopausal women
with ER positive and/or PR positive early breast cancer. Randomisation was to either
five years exemestane or 2.5-3 years tamoxifen followed by 2-2.5 years exemestane.
A prospectively powered pathology sub-study is underway, recruiting 5000 cases
from 5 countries to prospectively test two molecular hypotheses: (1) PR poor
tumours relapse early during tamoxifen treatment and may benefit from early
treatment with AIs, (2) Type I receptor tyrosine kinases (HER 1-3) abnormalities are
associated with resistance to tamoxifen and HER 1 -3 positive cases may also benefit
from early treatment with AIs (135-137). These biomarkers are currently being
measured by immunohistochemistry (IHC) and FISH (in the case of HER2) in this
trial. IHC has been previously shown to correlate well with biochemical assessment
of steroid receptors in breast cancer tissues (138). Analysis of ER and PR expression
levels is conventionally performed using manual assessment of staining patterns
using the histoscore or simplified scoring systems (such as the Allred score) and
despite evidence that such approaches can be robust (139), novel high-throughput
image analysis technologies offer the opportunity to produce consistent, accurate and
reproducible results without the potential for human error (139-141). This is
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especially critical since it is emerging that response to therapy is often a quantitative
phenomenon dependent on the concentration of protein within the tissue, suggesting
robust and quantitative methodologies are important in such analyses (142; 143).
Computer-assisted image analysis systems have been used to improve quantification
and reproducibility of IHC almost since the introduction of ER IHC into clinical
practice 20 years ago (144-147). Although staining intensity by computer-assisted
measurement is more consistent than human assessment due to lack of interference
by variability in ambient light or fatigue, there remain challenges in analysing
complex tissues containing both epithelial and stromal compartments and infiltrates
of benign cells such as inflammatory cells. However, over the last few years,
hardware and software advances have made semi- automated computerised image
analysis a viable option for high-throughput analysis of protein biomarkers in tissue
sections and tissue micro-arrays.
Here we validate a semi-automated image analysis approach using the Ariol system
(Genetix Applied Imaging) for standard chromogenic immunohistochemical
assessment of ER and PR in nearly 600 patients from the TEAM study in tissue
microarray (TMA) format.
3.2 Methods
3.2.1 Samples and TMA construction
All patients recruited into the UK TEAM trial were approached prospectively for
written informed consent to donate tissue samples to the pathology sub-study. Where
consent was given, tissue blocks were retrieved from the local pathology laboratory
and sent to the central pathology laboratory. Following H&E sectioning, tumour
areas were marked for TMA construction and 0.6mm" cores placed into 6 separate
TMA replicates for each sample. For this validation study, samples from 3 TMAs
were used, containing 595 cases. Full sections of cases from one TMA (containing




IHC was performed according to standard protocols. Briefly, tissue sections were
dewaxed in xylene and rehydrated. Antigen retrieval was performed using heat
treatment under pressure in a microwave oven for 5 min (ER) in Tris-EDTA buffer
pH8.0 or 4 min (PR) in citrate buffer pH6. Sections were blocked for endogenous
peroxidase followed by incubation with anti-ER or PR antibodies (ER clone NCL-L-
ER-6F11; Novocastra, 1:50 dilution, PR clone 636; Dako, 1:50 dilution) for 60 min
at room temperature. Staining was developed using EnVision (Dako, Denmark) and
DAB (Dako, Denmark) before slides were counterstained in haematoxylin,
dehydrated and mounted in DPX. Stringent quality control was adhered to reduce run
to run variation.
3.3.3 Manual evaluation of ER, PR
Two observers scored all whole sections and TMA cores for ER and PR
staining intensity following training in IHC as described previously (139). For each
section or core the percentage of cells staining 0, 1+, 2+ and 3+ were recorded and a
histoscore (0-300) for IHC staining was produced.
3.3.4 Image analysis
For image analysis the TMAs were scanned onto the Ariol SL-50 image analysis
system, as previously described (148). Briefly, three-colour filtered images were
captured on a black-and-white CCD camera and reconstructed by the supplied
proprietary software. Tumour areas were marked by one observer and quality
controlled by a second observer and pathologist. The system was trained on the basis
of the cellular characteristics (shape, size, and colour) of epithelial, stromal, and
infiltrating non-tumour cells to produce a trained classifier applicable to all nuclear
stains, which would largely exclude any contaminating cells (stromal cells or
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lymphocytes) from the analysis. For both ER and PR an analytical algorithm was
trained using one TMA set of 198 cases (stained in sextuplet), after which analysis
was performed without human intervention (other than for tumour marking) i.e. once
parameters were set these were used for the rest of the study.
3.3.5 Statistics
Histoscores from automated analysis of TMAs were calculated from the sum of cells
from all cores (2-6 cores/case), not by averaging histoscores from each replicate
core. Automated histoscores were excluded from analysis if they were derived from
<100 objects (cells), with 2 cores/case this led to the exclusion of a significant
number of cases due to low cell numbers. The inter-observer variation between the
scoring of nuclear ER and PR by manual and automated methods was assessed by
measuring both Pearson regression coefficients (PRC) and Inter Class Correlation
Coefficients (ICCC) statistics. ICCC is a measure of bias assessing the amount of
systematic data variance by comparing the variability of each independent observer
for each case with the overall variation between all scores, as previously described
(149-151), (139). For all PCCs, p values were less than 0.0001.
3.4 Results
3.4.1 TMA analysis is representative of whole section scoring.
All sections and TMAs included in this study were manually scored by two
pathology technicians (TR and CK) trained in the assessment of
immunohistochemical staining using identical criteria as for pathologist assessment,
prior to commencing this analysis both observers demonstrated excellent intra and
inter-observer consistency in scoring in line with our previously published criteria
(152). Pathological QA ensured that scoring was always performed on invasive
tumour. Observer variation, as assessed by PRC and ICCC, was excellent. An
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excellent to good correlation between observers for whole section analysis was
observed for ER (PRC 0.92, ICCC 0.87, n = 189) and PR (PRC 0.95, ICCC 0.91, n =
197). For TMA analysis correlation between observers was also good for both ER
(PRC 0.88, ICCC = 0.85, n = 394) and PR (PRC 0.97, ICCC = 0.94, n = 393).
The correlation between manually scored TMAs and manually-scored sections was
assessed for both PR and ER. An excellent correlation was observed between TMA
scores for PR (6 replicate cores: PRC = 0.91, ICCC = 0.90, n=197, Figure 3.1 A) and
an adequate correlation for ER (6 replicate cores: PRC = 0.80, ICCC = 0.56, n=189
Figure 3.IB). These correlations also held for fewer numbers of cores (3 replicate
cores: PR PRC = 0.90, ICCC = 0.88, n=196, ER PRC = 0.79, ICCC = 0.60, n=188).
The correlation for ER was biased by the small number of ER poor cases (<5%). As
reported previously (153; 154), TMAs are an excellent high-throughput methodology
for clinical trial biomarker analysis and representative of whole section analyses,




Con; Average (6refCcates) Core Average (6 repfecates)
Figure 3.1: XY plots and linear regression analysis of comparison between
whole sections and TMA cores (six replicates) for PR (A) and ER (B).
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Figure 3.2: Comparison between manual and automated scoring methods. (A)
XY plots and linear regression analysis of training and test TMAs for PR and ER
show excellent reproducibility when training classifiers are applied to an independent
test-set. (B) Number of assessable cores, number of cases (n) (% in brackets) and
correlations between manual and automated TMA scores (left) and changes in linear
regression (right). Only slight benefit in correlation coefficients is observed when
greater than one core is analysed, but more cores are required in order to overcome
loss of cores and missed cases.
3.4.2 Manual scoring versus automated image analysis.
Cell classifiers for both positive (DAB stained) and negative (haemotoxylin stained)
tumour cells were defined on a training set of tumours (n = 198 (n=186 and n=190
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available for analysis for PR and ER respectively); Figure 3.2A, left panels). Manual
versus automated histoscores showed excellent correlation for both PR (PRC = 0.95,
1CCC 0.95) and ER (PRC = 0.94, ICCC = 0.87). These classifiers were then applied
to a second independent test set (n = 199 (n=193 and n=194 available for analysis for
PR and ER respectively); Figure 3.2A, right panels), and excellent correlations for
both PR and ER were preserved (PR: n = 193; PRC = 0.96, ICCC 0.96, ER: n = 194;
PRC = 0.97, ICCC 0.91). Finally, the same classifiers were applied to a larger cohort
of tumours including the test set and a third TMA set of 198 cases (n = 384 and 388
for PR and ER respectively). Excellent and good concordance were again
demonstrated for PR and ER respectively (6-core replicates, PR; PRC = 0.97, ICCC
= 0.96, ER; PRC = 0.95 ICCC = 0.93).
3.4.3 How many cores recapitulate the ER/PR expression seen in
tumours?
For both ER and PR we used 6 replicate 0.6mm2 cores (a total 3.6mm2). In order to
assess the number of replicates required to accurately recapitulate manual results we
performed regression analysis between manual and automated scores for both ER
and PR (Figure 3.2B). The inclusion of a greater number of cores did not reveal
marked improvements in correlations between manual and automated scores for
either PR or ER. However, the number of cases with sufficient data to report rose
markedly from an average of 81.2% with 2 cores assessed to 94.1% with four cores
and 97.2% with 6 cores, because of the exclusion of cases with less than 100 nuclei
counted by the automated system. Cases with less than 100 nuclei were deemed
unrepresentative of the tumour and were excluded from analysis.
3.5 Discussion
A comparison of manual and automated image analysis techniques on TMAs shows
that image analysis is an excellent alternative to manual scoring for ER and PR
nuclear stains. There were no significant improvements in correlation when more
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than 1 core was analysed, but this was offset by the lower number of cases available
for analysis when fewer replicates were used, due to the stringent exclusion
parameter of 100 nuclei. The PCCs and ICCCs for PR and ER were always excellent
(>0.94 and >0.90, respectively). Semi-automated image analysis can be used in place
of manual scoring for ER and PR performed on TMAs in clinical trials with potential
for greater consistency and quantification.
The analysis of tissue biomarkers within large patient cohorts by in situ methods (for
example immunohistochemistry, ISH, proximity ligation assays (148; 155;156))
requires consistent, accurate and reproducible high-throughput methods. Tissue
microarrays have advantages in improving the consistency of analysis by requiring
far fewer staining runs, reducing run to run variation and improving throughput. For
example this approach allows the analysis of the 5000 cases for ER/PR in the TEAM
trial in 6 IHC runs rather than the approximately 150 runs required for whole section
staining. However, it is critical that such methods be appropriately validated. It has
previously been shown that consistent and accurate scores can be obtained by manual
observers in relatively small data sets (100's of cases) (139), but clinical trial
databases often contain several thousand samples. Image analysis, with appropriate
quality control, may provide a simple and consistent assessment of staining with
greater precision, lower variation between runs, and ultimately yield additional data
not previously captured by manual observers. We have validated the analysis of
nuclear biomarkers, in particular ER and PR, by replicate TMA core analysis within
the context of the TEAM trial using the Ariol automated image analysis system to
capture images, quantify both DAB positive (stained) and negative (unstained)
nuclei, and process case scores for ER and PR staining intensity in the context of
quality assured ER and PR assays performed to GCLP standards. IHC methods and
interpretation were standardised in a centralised laboratory.
Data presented here supports the use of TMAs to recapitulate whole section scores
for PR and ER (see Figure 3.1) as has been previously reported by other observers
(154). Secondly, and more critically, we have evaluated the use of semi-automated
image analysis for the quantitative analysis of ER and PR staining using both training
and validation sets for both markers. We have shown that consistent results can be
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obtained when comparing ER and PR scores from two trained manual observers with
those obtained using the Ariol Image analysis system. We note that as few as 2 cores
give consistent results between manual and machine analysis.
The population analysed forms part of the pathology sub-study within the Tamoxifen
versus Exemestane Adjuvant Multicentre (TEAM) Trial which recruited ER positive
breast carcinomas to a trial investigating the potential benefit of upfront versus
switch strategies for treatment of hormone receptor positive breast cancer with the
aromatase inhibitor Aromasin. Results for both ER and PR staining in both the
training and validation sets used in the current study showed excellent correlations
between manual and machine derived scores across the observed expression range.
Also we observed that the use of image analysis allowed a greater discrimination
between the staining intensity of strongly staining ER positive cells (which was not
observed by manual scoring), enhancing the information derived from ER
quantification, which could reflect the fact that human observers often group together
observationally distinct 'strong' and 'very strong' nuclei. This resulted in slightly
lower automated scores for tumours with high ER expression. Whilst the biological
significance of this added discrimination achieved by image analysis is not yet clear,
it provides an important potential improvement in assessment of ER staining by IHC
methods.
A second, potentially highly significant, advantage of the image analysis approach is
results are based upon the quantification of expression in individual cells rather than
broad categorisation. All manual interpretation systems currently used for ER and PR
analysis rely on human observers estimating the percentage of stained cells and the
intensity of staining. This estimation requires the grouping of results into categorised
scoring systems (Allred, Quick Score); even the Histoscore, which represents the
best attempt at approximating quantification of expression, is a categorised variable
(albeit with 301 potential sub-categories). By integrating results from individual cells
using a continuous scale for estimation of staining intensity image analysis systems
evaluate marker expression as continuous variables based on cell by cell data. This
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provides significant advantages over categorised estimates, the full potential of
which remains to be explored.
However, one continued challenge remaining with image analysis is the progression
to fully automated systems. Whilst the Ariol system provided excellent consistency
with manual observers based on automated analysis of staining intensity and
frequency, it was not able to accurately discriminate between tumour and non-
tumour components within tissues. Each tissue sample was individually marked for
tumour content by trained pathology technicians and quality assured by a second
trained individual, with reference to a pathologist where appropriate. This task is
highly time consuming but at present remains an essential step to ensure accurate
determination of tumour marker expression. Preliminary data suggest modification of
counter staining procedures may ultimately allow for fully automated analysis which
will greatly expedite future sample analysis.
A large recent study has shown that automated quantification by Ariol automated
analysis of ER in breast cancer has similar prognostic significance to pathologist-
scored ER values, and that concordance between machine and pathologist, and
machine and biochemical assay, were high (148). Our data supports the use of both
TMAs and image analysis, with appropriate quality assurance procedures, for the
assessment of steroid hormone receptors in large breast cancer clinical trial
databases. Indeed image analysis provides a more detailed quantification of
biomarkers and may provide additional information about concentration dependent
alterations in ER and PR and the biology of breast cancer. In this regard there are
similarities between this approach, the analysis of DAB stained biomarkers and
immunofluorescence approaches such as AQUA (123). Although fluorescent-based
analysis offers theoretical advantages over IHC in terms of wide dynamic range and
linearity of detection signal, and has shown significant promise in the research
setting, immunofluorescent assays are not yet standard for diagnostic histopathology.
However, while Ariol analysis is sensitive and specific for nuclear biomarkers,
significant challenges exist in image analysis using this system when trying to
discriminate other compartments, both at tissue (epithelial vs stromal) and
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subcellular (ie membrane and cytoplasmic) level. Immunofluorescence-based
techniques such as AQUA offer significant advantages in this regard, since
molecular markers detected on different channels (such as cytokeratin for epithelial
cytoplasmic compartments) accurately delineate both subcellular and epithelial
compartments. Direct comparisons between quantitative conventional
immunohistochemistry and immunofluorescence will be required to determine which
approach is most valuable in the management of breast carcinomas in the long term.
ER and PR are critical biomarkers for the evaluation of breast carcinomas. The use of
both tissue microarrays and image analysis are appropriate for the analysis of large
data sets where quantitative information on ER and PR expression is required.
Further comparisons with immunofluorescence would be of significant value, and




Chapter 4: Describing Pathways (1): The reductionist approach.
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4.1 Introduction
In Chapters 1 and 2 we discussed the need for a more systematic analysis of pathway
biology in order to understand therapeutic responses to targeted therapies, and in
Chapter 3 one approach to improving quantification from tissues. In order to
accurately describe network topology (ie the structure of the interactions between
molecules), reductionist cellular and molecular biology still plays a role in filling in
the detail of these interactions. Existing models (including our own, see Chapter 6) of
receptor tyrosine kinase (RTK) signalling focus on the immediate phosphorylation
events of kinases within signalling cascades, but these are only accurate over a few
minutes since other mechanisms, such as transcriptional feedback, are soon activated.
In order to pave the way to expanding existing models of RTK signalling to include
such transcriptional events which are known to feed-back onto RTK pathways, we
investigated the control of Sprouty-family proteins, which are negative regulators of
PI3K and MAPK signalling, and activated as delayed early genes. In doing so we
also investigated the effects of Sprouty proteins on trastuzumab sensitivity and
resistance.
Although the HER2-targeting RTK inhibitor trastuzumab has clinical efficacy in
both early and metastatic breast cancer, measurement of HER2 protein expression or
gene amplification status is a poor predictor of response with a low positive
predictive value (157; 158). The documented benefit of adjuvant trastuzumab
combined with chemotherapy vs chemotherapy alone in terms of overall survival in
HER2 positive patients is modest (96% vs 95% respectively at 1 year) (157) and
91% vs 87% respectively at 4 years (158). A large proportion of patients therefore
unnecessarily receive ineffective and expensive treatments with toxic side-effects,
and mechanisms of resistance need to be elucidated in order to more efficiently select
patients who will respond to therapy. As previously mentioned, suggested
mechanisms of de novo and acquired resistance to trastuzumab include PIK3CA
activating mutations, PTEN inactivation, IGF1R over-expression and expression of
p95 HER2 isoforms (71;72;159). Although much attention has been paid to
'forward-signalling' mechanisms of pathway activation such as activating mutations
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in cellular oncogenes (eg RAS, RAF or PIK3CA), it is as likely that loss of negative
feedback control also causes aberrant pathway activation, such as is the case with
mutation or decreased protein expression of PTEN. We hypothesised that one of the
best characterised and potent EGF-induced negative feedback regulators, the
Sprouty-family of proteins (160-166), also may be activated as a feedback inhibition
programme downstream of HER2 receptor, and therefore contribute to sensitivity or
resistance to trastuzumab.
To date there have been no reports implicating Sprouty in therapeutic sensitivity or
resistance. The only published report of expression of Sprouty in breast cancer
showed decreased expression at transcript level of Spryl and Spry2 in 78% and 96%
respectively of a small panel of breast cancers (n=50) (167). In spite of persistent
attempts to establish the underlying mechanism for decreased expression, the exact
cause remains elusive and may be different for specific orthologues in different
cancers. In prostate cancer, there is conflicting evidence regarding the epigenetic
regulation of Spryl, Spry2 and Spry4, with some authors showing that Spry2 and
Spry4 are downregulated by hypermethylation (168; 169), although in a separate
study no hypermethylation of the promoter region of Spry2 was identified (170).
Likewise, loss of heterozygosity (LOH) of Spry2 has been found in prostate cancer
(168), but not in other cancers. In breast cancer, none of the Sprouty family members
are downregulated by either LOH or epigenetic mechanisms. Given the dynamic
nature of Sprouty expression in response to ligand drive, it is possible that detection
of low expression levels reflects the activation state of the signalling network rather
than a genetic or epigenetic phenomenon.
Our objectives were to establish: (1) whether Sprouty-family members are associated
with established clinicopathological parameters in breast cancer, (2) whether
Sprouty-family members are dynamically regulated as a delayed early genes
response downstream of the HER2 receptor, similar to that seen with EGFR, FGFR,
and VEGFR, and (3) establish what role, if any, Sprouty expression levels play in
therapeutic resistance and sensitivity to trastuzumab. In addition, these data may be
used in the future to expand mathematical models of RTK-signalling.
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4.2 Methods
4.2.1 Microarray analysis from meta-analysis on ONCOMINE database.
The expression of Sprouty-family transcripts in breast cancer tissues was obtained
from meta-analysis of cancer gene microarray meta-analysis public database,
representing analysis of over 390 microarray studies (171). Statistical analysis of
differences was performed using ONCOMINE algorithms to account for the multiple
comparisons among different studies, similar to a meta-analysis, as previously
described (171). Comparison of normal tissue and breast cancer were performed on
(172) (n=47; 7 normal vs 40 breast carcinomas), grade comparisons on (173) (n= 60;
3 grade 1 vs 39 grade 2 vs 18 grade 3) and HER status on (174) (n=50; 32 HER2
negative vs 18 HER2 positive).
4.2.2 Cell culture and western blotting.
MCF-7, MDA-MB-231, MDA-MB-361, MDA-MB-453, MDA-MB-468, SKBr3,
ZR75-1, BT20, and BT474 breast adenocarcinoma cell lines were grown as
monolayer cultures in DMEM supplemented with 10% heat-inactivated foetal calf
serum (FCS) and penicillin / streptomycin (lOOIU/mL) in a humidified atmosphere
of 5% C02 at 37°c, except for MCF10A (MEBM with hydrocortisone, hEGF 10
|ig/ml, insulin, cholera toxin and horse serum). Time course experiments were set up
by plating cells into 10cm 0 petri dishes and leaving for 48h. Cells were then briefly
washed in PBS before transferring to phenol red-free DMEM containing 5% double
charcoal-stripped serum supplemented with penicillin / streptomycin (lOOIU/mL)
and glutamine (0.3mg/mL) for a further 48h prior to treatment. Paired lysates were
prepared by first treating relevant dishes with pertuzumab (lOOnmol/L; a kind gift
from Roche, Basel, Switzerland) immediately followed by the addition of heregulin-
P (lnmol/L). Samples were collected at time points of 1, 2, 5, 10, 30, or 60 min,
washed in PBS, and immediately lysed in ice-cold isotonic lysis buffer supplemented
with aprotinin (10 pg/mL) and protease inhibitors (Roche, 11836153001). Protein
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lysates were electrophoretically resolved on either 10% or 12% SDS-PAGE and
transferred overnight onto Immobilon-P membranes (Millipore, Bedford, MA).
Primary antibodies used for western blotting were: anti-phospho-AKT (Ser473) (Cell
Signaling Technology, #4060) at 1:1000; anti-phospho-p44/42 MAP Kinase
(Thr202/Tyr204) (Cell Signaling Technology, #9101) at 1:1000; anti-phospho-HER2
(Tyr877) (Cell Signaling Technology, #2241) at 1:1000; anti-phospho-HER3 (Tyr1289)
(Cell Signaling Technology, #4791) at 1:1000. Immunoreactive bands were detected
using enhanced chemiluminescent reagents (Roche; 1520709) and Hyperfilm ECL
film (GE Healthcare, UK), and Integrated Optical Density (IOD) absorbance values
were obtained by densitometric analysis using Labworks (UVP Life Sciences,
Cambridge, UK).
4.2.3 RNA extraction and reverse transcription
Total RNA was extracted from cell lines using RNA extraction kits, as recommended
by the manufacturer (Qiagen, GmBH, Hilden, Germany). RNA was treated with
RNase-free DNase I (Qiagen) for 30 min at room temperature. Reverse transcription
reactions were performed according to manufacturers' protocols with 1 jug of DNase-
treated RNA, using the High Capacity cDNA Archive Kit (Applied Biosystems),
25°C for 10 min, 37°C for 120min, 85°C for 5s.
4.2.4 Quantitative Real-Time PCR
For each PCR reaction, 2pl of cDNA was mixed with 1 ml 20x primer assay
mastermix containing a final concentration of 900nM of each primer and 250nM
FAM dye-labeled TaqMan MGB probe (hSPRYl assay ID Hs00398096_ml,
amplicon size 78bp, hSPRY2 assay ID Hs00183386_ml, amplicon size 86bp,
hSPRY3 assay ID Hs00540086_ml, amplicon size 73 bp; TaqMan Gene Expression
Assay, Applied Biosystems), 10 pi 2x TaqMan Universal PCR MasterMix, and 7 pi
distilled water. Reactions were carried out using the Applied Biosystems 7900HT
Real Time PCR system according to manufacturers' instructions. Reactions were
carried out in triplicate. Relative changes in gene expression were calculated using
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the AACt method between untreated controls, MCFlOa cell lines and RPL37a
(reference) gene products.
4.2.5 Constructs, transfection, and cell viability.
The FLAG-hSpry2 and FLAG-HSpry2Y55F constructs were a kind gift from Dr
Graeme Guy (Signal Transduction Laboratory, Institute of Molecular and Cell
Biology, National University of Singapore) and used as previously described
(175; 176). In addition, empty pXJ40FLAG vector was constructed by digesting
hSpry2-containing pXMOFLAG vector at BamHl and Bglll restriction sites. Both
mutant and normal sequences were verified by DNA sequencing, and empty vector
confirmed by gel electrophoresis. At 70% confluence, cells were transfected with 1-2
pg of FLAG-tagged plasmid DNA using Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer's instructions. On the following day, the cells were
trypsinised and plated into 96-well plates at a concentration of 1000 cells/well. The
cells were treated with or without trastuzumab (10 |a.g/ml) for 24 or 48 h. Cell
viability was measured using the AlamarBlue reagent (AbD Serotec), according to
manufacturer's instructions.
4.2.6 Samples and tissue microarray construction.
The population characteristics of the trastuzumab-treated cohort is summarised in
Appendix A. HER2 gene amplification status was determined by fluorescence in situ
hybridisation (FISH; DAKO HER2 FISH PharmDx, Ely, Cambridgeshire. The study
was approved by the Lothian Research Ethics Committee (08/S1101/41). Overall
survival was calculated from date of initial diagnosis to date of death by any cause.
Following H&E sectioning of representative tumour blocks, tumour areas were
marked for TMA construction and 0.6mm2 cores placed into 3 separate TMA
replicates for each sample, as previously described (177).
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4.2.7 Immunofluorescence and AQUA automated image analysis.
A detailed description of the AQUA HistoRx methodology is available elsewhere
(123; 178). Briefly, slides were incubated with primary antibodies diluted in 0.025%
PBST for 1 h at room temperature (AE1/AE3 mouse monoclonal cytokeratin
antibody, rabbit polyclonal to hSpry2 (Novus Biologicals) diluted 1:100 and 1:25
respectively. Pan-cytokeratin antibody was used to identify infiltrating tumour cells
and normal epithelial cells, DAPI-counterstain to identify nuclei, and Cy-5-tyramide
detection for target (hSpry2) for compartmentalised (tissue and subcellular) analysis
of tissue sections. hSpry2 antibody specificity was determined by a single band on
western blot and correct (epithelial) cellular localisation.
4.2.8 Statistics
AQUA scores were averaged from replicate cores, and cores containing <5%
malignant epithelium were excluded. We used the software programme, X-Tile, to
determine the optimal cutpoint while correcting for the use of minimum P statistics
(179), which is known to inflate type I error when used incorrectly (180). Two
methods of statistical correction for the use of minimal P approach were utilised, the
first calculation of a Monte Carlo P-value and for the second, the Miller-Siegmund
minimal P correction (180). Overall survival was subsequently assessed by Kaplan-
Meier analysis with log-rank for determining statistical significance. Relative
risk was assessed by the univariate and multivariate Cox proportional hazards model.
Comparison of differences in means in vitro was performed using the Student's T-
test. All calculations and analyses were two-tailed where appropriate and done with
SPSS 14.0 for Windows (SPSS, Inc., Chicago IL).
4.3 Results
4.3.1 Sprouty-family members are differentially expressed in
clinicopathological subgroups of breast cancer and in breast cancer
cell lines in vitro.
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We first interrogated published gene expression profiles to assess the expression of
Sprouty-family proteins according to clinicopathological parameters (Figure 4.1).
Sprouty 3 was omitted from the analysis since this is considered a minor orthologue.
Spryl, Spry2 and Spry4 show decreased gene expression in invasive breast
carcinomas compared to normal breast, consistent with previous reports (167). Loss
of Spryl and Spry2 expression is significantly associated with high grade tumours, in
contrast to Spry4 gene expression, where increased expression is present in high
grade disease. Spryl and Spry 4 show increased expression in HER2-positive breast
tumours, while Spry2 is decreased.
















Figure 4.1: Gene expression of Sprouty-family members according to the
clinicopathological parameters, using the ONCOMINE online resource.
Comparisons between groups were analysed as previously described (171), and
differences between groups were highly significant (p<0.001).
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We next investigated whether similar gene expression patterns were present in breast
adenocarcinoma cell lines. Quantitative gene expression analysis of Spryl, Spry2 and
Spry4 confirmed >2-fold downregulation of Spryl, Spry2 and Spry4 in 60%, 70%
and 80% of cell lines respectively when compared to the immortalised 'normal'
MCF-10A breast epithelial cell line (Figure 4.2a). The magnitude of downregulation
was frequently large, with 20%, 60% and 30% of cell lines showing >100 fold
downregulation of Spryl, Spry2 and Spry4 respectively. We next investigated
whether the differential gene expression of Sprouty in HER2low vs HER2hlgh tumours
occurred in vitro. Decreased expression of Spry2 (Student's T-test, p=0.036; Figure
4.2b), but not Spryl or Spry4 (p=0.10 and p=0.37 respectively) was observed in cell
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Figure 4.2: In vitro analysis of Sprouty gene expression, a, Analysis of cell lines
by quantitative real-time PCR shows profound downregulation of Spryl, Spry2 and
Spry4 in a high proportion of breast cancer cell lines when compared to the
immortalised 'normal' MCF-10A breast epithelial cell line, b, Spry2 (Student's t-test,
p=0.036), but not Spryl or Spry4 are associated with increased protein expression of
HER2.
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Although the HER2-amplified cell lines SKBr3, BT474, and MD-MBA-361 all
showed >2-fold reduction in gene expression, several others also showed large-
magnitude downregulation. We reasoned that since Sprouty was associated with
HER2 protein expression, and that Sprouty is infrequently mutated or epigenetically
silenced in cancer, Sprouty gene expression could be dynamically regulated through
HER2-directed growth signalling pathways as well as through EGFR-mediated
pathways (181-183).
4.3.2 Sprouty-family members are dynamically expressed as delayed
early genes downstream of HER2/HER3.
In order to test this hypothesis, we stimulated BT474 cells, which showed the lowest
steady-state expression of Spry2 and intermediate expression of Spryl and 4, with
heregulin-P in order to drive signalling through the HER2/HER3 signalling axis.
BT474s cells express low levels of HER1 and HER4, and intermediate levels of
HER2 and HER3, with low-level amplification of HER2. All three Sprouty
transcripts showed an increase in expression by 4 h consistent with a delayed early
gene (DEG) response as previously described for signalling with EGF and FGF
(Figure 4.3a). To show that the effect was dependent on HER2 signalling, cells were
treated with the HER2 dimerisation inhibitor pertuzumab, which completely
abrogated the Sprouty transcriptional response (Figure 4.3a).
Since Sprouty proteins are known to feed back onto the canonical MAPK growth
factor signalling pathway, which cross-talks with PI3K cell survival pathway via
RAF and protein phosphatases, and interact with PI3K signalling directly via PTEN
(184), we investigated the dynamics of activation of ERK, PI3K and upstream
receptor activation using phospho-specific antibodies to pAKT (Ser473), phospho-
p44/42 MAP Kinase (Thr202/Tyr204, and pHER2 (Tyr877) in response to heregulin-(3
and pertuzumab (Figure 4.3b). pHER2, and pERK were transiently activated with
return to low steady-state levels after 24 h, in response to heregulin, while activation
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Figure 4.3: Gene and protein expression of Sprouty-family members over time.
a, Quantitative real-time PCR analysis of dynamic expression of Spry I, Spry2 and
Spry4 over 24 hours in BT474 cells in response to heregulin-(3 (blue line) and
heregulin-P plus pertuzumab (red line) shows that Spry is expressed as a delayed
early gene. Expression levels are relative expression compared to untreated controls
at time = 0 min. b, Timecourse profiles of receptor activation (HER2 and HER3),
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Figure 4.4: Western blots of pAKT and pERK activation at 24 and 48 h in
trastuzumab sensitive (BT474) and trastuzumab resistant (SKBr3) breast cell
lines. Cells were treated with or without trastuzumab (lOmg/ml) in control, Spry2 or
Spry2Y55F transfected lines. All experiments were repeated at least twice.
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Inhibition with pertuzumab inhibited phosphorylation of HER2 and HER3,
consistent with dimerisation inhibition, caused a sustained decrease in pAKT, but
had little effect on pERK dynamics. Sprouty expression therefore appears to be
temporally decoupled from downstream activation of effector proteins, indicating
complex interactions with effector pathways by Sprouty-mediated feedback
inhibitory loops in the physiological setting.
Nevertheless, transient expression of full length wild-type and dominant negative
Spry2Y55F had the expected effect on ERK signalling, causing decrease and increase
in pERK expression at 24 h in both BT474 and SkBr3 breast adenocarcinoma cell
lines (Figure 4.4), confirming the regulatory effect of Sprouty under experimental
conditions.
4.3.3 Spry2 acts synergistically with trastuzumab to reduce cell viability
in vitro, and forced feedback inhibition with chemical inhibitors have a
similar effect.
Since Spry2 is most closely associated with HER2 status, we next investigated what
the effect of altering steady-state expression of Spry2 was on cell growth and
therapeutic response, using transient expression of wild-type and dominant negative
Spry2Y55F. SkBr3 breast adenocarcinoma cell lines were insensitive to treatment with
trastuzumab, while BT474s were sensitive at 48 h (Figure 4.5) when grown in full
serum conditions. Overexpression of empty vector, Spry2, or Spry2Y55F dominant
negative construct resulted in no significant changes in growth in either of the cell
lines at 48 h. However, overexpression of Spry2 significantly increased sensitivity to
trastuzumab at 48 h in trastuzumab-insensitive SKBr3s, but there was no difference
in growth in BT474s with either the full length or dominant-negative constructs.
Spry2 inhibited both pERK and pAKT in SkBr3s, but not BT474s, suggesting that
Sprouty can synergise with trastuzumab via either inhibition of ERK or PI3K
signalling. Re-establishing feedback inhibition in Sprouty-low tumours may
therefore be an effective strategy for combinatorial therapy with trastuzumab, and
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raises the possibility that in some HER2 overexpressing tumours, high expression of
Spry2 may be a marker of response to trastuzumab. We tested the combinatorial
approach in vitro by substituting the negative feedback control of ERK and P13K
signalling of Spry2 with the chemical inhibitors LY294002 and PD98059, which
inhibit PI3K and MEK1 respectively, with and without treatment with trastuzumab.
As expected, trastuzumab showed little effect on cell viability alone, but a synergistic
effect when SKBr3 cells were pretreated with LY294002, inhibiting growth by 29%
at 24 hours (Figure 4.5). Forcing feedback inhibition through combinatorial
approaches may therefore be a novel therapeutic strategy in tumours with a priori
trastuzumab resistance.
LV294C02 PC-93C59 H«r<«ptin LV294C02 ♦ PD93C59*
H<rcepbn Hirceptin
Figure 4.5: Sensitivity of trastuzumab sensitive and resistant cell lines in vitro
with variable Spry2 expression, a, Cell viability (AlamarBlue) assays to assess the
effect of Spry2 on sensitivity to trastuzumab in trastuzumab resistant SKBr3s (left
panel) and trastuzumab sensitive BT474s (right panel). Values are % cell viability
compared to untreated controls. Expression of full length Spry2 results in a
significant decrease in cell viability (asterisk, Student's t-test, p=0.0008) compared to
control or dominant negative Spry2Y55F. b, Trastuzumab and LY294002 show
synergistic inhibition of cell viability (asterisk, Student's t-test, p=0.042) in
trastuzumab-resistant SKBr3 breast cell lines.
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4.3.4 Low Spry2 expression is associated with resistance to
trastuzumab in trastuzumab-treated patients.
Since higher levels of Spry2 were responsible for increased therapeutic efficacy in
the HER2+ SKBr3 breast cell line, we quantified expression of Spry2 in 122 primary
breast tumours from patients who had been treated with trastuzumab using the
AQUA fluorescence image analysis system (Figure 4.6). This allowed us to test
whether high expression levels of Spry2 protein were associated with trastuzumab
sensitivity, and low expression levels with resistance, in the clinical setting. The
cutpoint for Spry2 expression were calculated as described above, such that as well
as showing high significance for difference in survival (p=0.0069), the cutpoint for
Spry2 expression also maintained good significance with Monte Carlo simulations
(p=0.09) and correction for type I error (Miller-Seigmund p value = 0.12). In
univariate analysis, tumour size, ER status, chemotherapy regimen, and Spry2
expression levels were all associated with significant survival differences (log-rank
test, p<0.05, Appendix A), but Spry2 remained the only significant predictor of
survival in multivariate analysis (Cox logistic regression, p=0.002). Consistent with
the findings in vitro, high levels of Spry2 expression were associated with better
overall survival than patients with tumours which expressed low levels of Spry2 (HR
= 2.28, 95% CI 1.22 - 4.26; p=0.008; mean survival 48 (95% CI 41-54 months)
months vs 37 (95% CI 26-40 months) months for high and low Spry2 levels,
respectively; Figure 4.6b). This supports the role of Spry2 as a tumour suppressor
gene in breast cancer, and its role in therapeutic resistance to trastuzumab.
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Figure 4.6: Quantitative expression of Spry2 is associated with trastuzumab
senstitivity in patients, a, AQUA fluorescent analysis of Spry2 expression in a
tissue microarray core, showing cytoplasmic localisation of Spry2 (red) and masking
of tumour areas for quantitation by cytokeratin (green), b, Kaplan-Meier survival
curves for patients treated with trastuzumab for low (red) and high (blue) protein
expression of Spry2. Overall survival is calculated from time of initial diagnosis to
date of death.
4.4 Discussion
The balance between positive and negative signals is critical in the maintenance of
normal cell homeostasis in response to external stimuli, whether the stimulus is
physiological (such as ligand drive) or therapeutic (such as with RTK or small
molecule inhibitors of cellular signalling). The clinical implications of feedback
control are becoming more readily appreciated. Loss of feedback inhibition in
tumours treated with mTOR inhibitors (via increased expression of IRS-1) results in
induction of AKT signalling, and may be responsible for the disappointing efficacy
of mTOR antagonists in the clinic (90). At worst, mechanisms such as unintended
negative feedback contribute to the poor efficacy of agents when studied in Phase II
and Phase III cancer trials and the high rate of attrition of drugs (approximately 30%
due to efficacy), which is both time consuming and expensive (91).
Here we investigated the role of one such feedback mechanism, Sprouty expression,
in breast cancer and therapeutic resistance to RTK-inhibitors. In breast cancer, Spryl
and 2 have been shown to be downregulated at gene expression level compared to
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normal breast epithelium (167), which we confirm by meta-analysis of published
gene expression data and confirmatory in vitro gene expression studies in a panel of
breast cancer cell lines. Also consistent with a tumour suppressor function, Spry] and
2 expression decreases with increasing histological grade, but Spry4 increases.
Variable Sprouty expression is not uncommon and reflects bimodal or complex
functions depending on context or orthologue. For example, Spry2 can have positive
effects on ERK signalling as well as negative effects through sequestration of cbl and
inhibition of cbl-mediated receptor ubiquitination and degradation (160), and Spry4
may play a greater role in cell fates other than proliferation or apoptosis, such as cell
spreading and motility (185), which would have a greater influence on other
pathological endpoints such as invasion and metastasis. Similarly, Spryl and 4 were
highly expressed in HER2 positive tumours, while Spry2 showed lower expression.
Since Sprouty expression was associated with HER2 status, has been shown to be
expressed as a delayed early response (DER) gene downstream of other closely
related growth factor receptors such as EGFR and FGFR, we further explored the
association with HER2 in order to establish whether Sprouty plays an important role
downstream of this therapeutically-targeted receptor. Interrogation of a panel of
breast carcinoma cell lines confirmed the expression patterns from array analysis and
showed that decreased Spry2 is associated with HER2 protein expression level. Since
HER2 does not have any known ligands, and HER3 is kinase-dead, we exploited the
property of heregulin-(3 to preferentially drive signalling through HER2/HER3
receptor dimerisation (in preference to EGFR heterodimerisation) to show that,
similar to delayed early gene expression of Sprouty downstream of FGFR and
EGFR, Spry], 2 and 3 are expressed as DEGs with increased expression after 4 h,
which was sustained at 24 h. This effect was abrogated by the RTK dimerisation-
inhibitor, pertuzumab. Although transient expression of Spry2 or dominant negative
Spry2Y55F showed inhibition and induction of ERK signalling as expected,
physiological pathway activation with heregulin-|3 showed pathway activation
dynamics which were not obviously related to profiles of Spry2 gene expression,
suggesting that physiological control of signalling is more complicated than forced
expression within the experimental setting would suggest. Therefore there is an
additional explanation for altered steady-state expression of genes in cancer which
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are not mutated, epigenetically silenced by hypermethylation of promoter regions, or
have loss of heterozygosity, none of which have been shown for Sprouty in breast
cancer. Instead, steady state expression levels represent surrogates for the dynamic
state of related signalling pathways at that point in time, in this case Spry2 expression
in the face of HER2 overexpression.
We explored the cooperativity of feedback by Sprouty on overcoming therapeutic
resistance to trastuzumab by overexpressing Spry2 or dominant negative Spry2Y55F in
trastuzumab-resistant or sensitive cell lines expressing intermediate-levels of
endogenous Spry2. Full length Spry2 synergised with trastuzumab to inhibit growth
in trastuzumab insensitive SkBr3 cells. In some settings, therefore, reinstating
negative feedback can overcome trastuzumab resistance. Since no Sprouty mimetics
exist for therapeutic purposes, we used inhibitors of PI3K and ERK signalling,
LY294002 and PD98059 in place of Spry2 feedback, since Spry2 can inhibit ERK
directly or PI3K indirectly via PTEN. LY294002, but not PD98059, synergised with
trastuzumab to inhibit cell growth, suggesting that for cellular proliferation at least,
inhibition through PI3K is the dominant synergistic feedback mechanism. Steady
state levels of Spry2 were confirmed to have an impact on therapeutic response in a
series of 122 trastuzumab-treated breast cancers, with low Spry2 levels significantly
associated with decreased overall survival in multivariate analysis. Our data suggest
that in a proportion of breast tumours deficient in negative feedback, combinatorial
therapy with inhibitors of pathways downstream of RTKs may be an effective
therapeutic strategy, and negative feedback proteins such as Sprouty may be useful
biomarkers for selecting patients for these therapies.
Although in this chapter we suggest that high levels of Sprouty 2 are associated with
trastuzumab resistance, and that Sprouty expression changes at gene expression level
in the face of ligand drive, the exact relationship between the first measurement
(static) and the second set of measurements (dynamic) in real tissues remains to be
determined. Therefore input of equations describing the gene expression of Sprouty,
and inhibition of MAPK/PI3K pathway components by Sprouty, may lead to a
greater understanding of the relationship between steady-state levels of feedback
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proteins and ligand drive. Although not specifically included in our existing models
(see chapter 6), delayed early gene responses would be an attractive area for further




Chapter 5: Describing Pathways (2): The multiple pathway approach.
5.1 Introduction
Although it is clear from our own data (Sprouty (Chapter 4) and PTEN (Chapter 6)
and others (71 ;72; 159; 186; 187) that detailed understanding of canonical growth
factor pathways (such as MAPK/PI3K) is beginning to lead to advances in
understanding resistance mechanisms with respect to RTK-inhibitors, there also
needs to be discovery-driven advances in biomarker biology in order to meet the
rapid evolution of therapeutics available to the clinic. Much of this unmet need has
come from research using gene expression microarrays, but little of this has resulted
in useful clinical tests, for reasons already discussed. Given the complexity of
crosstalk between pathways, there is no definite a priori reason why some seemingly
unrelated pathways might not impact on each other in the face of therapeutic
perturbation. Moreover, many of the molecular mechanisms mediating responses to
'traditional' cytotoxic therapies (which are still the mainstay of adjuvant therapy for
many cancers) remain to be established. To date there have been few attempts to
deconvolute complexity across multiple pathways at protein level. Driven by our
desire to understand how different pathways interact at a systems level, and by a
need to develop new tools to discover markers of therapeutic response, we sought to
investigate how accurate measurements of pathways may be used to re-classify
cancers, using quantitative measurements from AQUA fluorescence image analysis.
Survival figures for epithelial ovarian cancer remain poor, with 65% of women dying
of their disease at five years (188), in spite of often initially good response rates to
chemotherapy (189). This is partly because women with ovarian cancer present with
late-stage disease, but also because of a lack of predictive tissue biomarkers coupled
with effective therapy in clinical practice or in the pipeline, in contrast to the clinical
success stories of ER, HER2 and others in breast cancer (84; 190). Most women are
treated with cytotoxic chemotherapy (usually platinum +/- taxane) (189), rather than
with lower toxicity targeted agents, such as tamoxifen or trastuzumab (Herceptin).
There is therefore an acute need to identify markers of sensitivity to existing
cytotoxic agents as well as to identify new 'hits' for targeted therapy in ovarian
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cancer, which could translate into real clinical benefit if currently available therapies
can be more precisely targeted to known dysregulated signalling in ovarian cancer.
Recent evidence suggests that distinct molecular subgroups of ovarian cancer exist,
both between (191) and within (192) recognised histopathological subgroups (serous,
endometrioid, clear cell, mucinous). This suggests that while histopathology alone
provides useful prognostic and predictive information, additional molecular profiling
may be able to resolve some of the heterogeneity in response. Molecular
classification at protein level may be more informative for therapeutic prediction
than gene expression profiling, which so far has only shown benefit in the
experimental setting (86). This is because drugs are designed to target proteins rather
than genes or transcripts in oncogenic or tumour suppressor pathways, which may
show as much as 60% difference to mRNA after post-translational modification. In
addition, the measurement of proteins is more readily adapted to clinical
histopathology labs, which already use immunohistochemistry as a standard
molecular technique, facilitating ready transition to the clinic.
The most useful protein targets to measure to meet these aims remain open to debate.
However, an emerging paradigm within cancer biology, and supported by recent
large-scale genotyping and transcriptional profiling studies (85), is that the
complexity of cancer can be reduced to abnormalities in suppression or activation of
only a few pathways, since several different mutations or transcriptional aberrations
within the same pathway can lead to similar phenotypes (193). To date, no attempt
has been made to classify tumours on the basis of pathway activation status, which
may be assessed by measurement of phosphorylated epitopes of key signalling
molecules. For example, phosphorylation of the serine 473 epitope of AKT provides
a measure of the activation state of the PI3K pathway (194). We hypothesise that
since experimental and clinically used agents already exist which target growth and
apoptotic pathways, classification of individual tumours by pathways could result in
a tumour specific signature which could guide patient-tailored therapy from a
number of readily-available and licensed agents, either alone or in combination.
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The aim of this part of our study was to (1) quantitatively measure the activation
state of eight growth- or survival-promoting pathways which are known targets of
current or experimental cancer therapeutics by generating a phosphoprotein profile in
cancer biopsy tissue (2) relate this to clinicopathological parameters including
histological subtype, proliferation, and apoptosis, and (3) establish whether this
approach can generate new testable hypotheses that allow prediction of therapeutic
responses.
5.2 Patients and Methods
5.2.1 Study population
The study population consisted of 168 epithelial ovarian tumours (48 serous, 30
endometrioid, 30 clear cell, 10 mucinous, 23 mixed epithelial, and 7 malignant
mixed mullerian invasive ovarian tumours, as well as 5 borderline serous and 14
borderline mucinous tumours) treated in the Edinburgh Cancer Centre between 1994
and 2005, as described previously (195). The study was approved by the Lothian
Research Ethics Committee (08/S1101/41). Summary patient characteristics are
shown in Table 5.1. Standard treatment included cytoreductive surgery followed by
platinum-based therapy, with or without combination with paclitaxel. Overall
survival was calculated from the date of diagnosis (primary surgery) to the date of
death by ovarian cancer, or to the date of last follow-up (censored). Patients who
died from disease other than ovarian cancer were censored.
5.2.2 Tissue microarray (TMA) construction
The construction of this TMA has already been described (195). Briefly, four
replicate TMAs were constructed using established techniques (196), and three
replicates were used for analysis within this study. Where primary lesions showed a
mixed histological pattern, representative areas of each histological type were
targeted, so that all types were adequately represented within the analysis.
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Well differentiated 12 7.9
Moderately differentiated 24 15.8









Table 5.1. Patient characteristics of ovarian cancer cohort.
5.2.3 Immunofluorescence
Immunofluorescence for phosphoprotein targets was performed using methods
previously described (197). The antibodies and conditions used within the study are
described in Table 5.2. Phosphoprotein specificity was determined by a single band
on western blot, positive tissue controls, epithelial specificity, and expected
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subcellular localisation, together with omission of primary antibody as a negative
control. Antibodies not meeting all of these criteria were rejected.
Target Supplier Dilution Antigen retrieval
pAKT(Ser 473) CST(#4060) 1:100 Sodium citrate pH6.0
pERK (Thr202/204) CST(#9101) 1:25 Sodium citrate pH6.0
pER (Serll8) CST(#2511) 1:500 Sodium citrate pH6.0
pbCatenin (Ser33/37/41) CST (#9561) 1:25 Sodium citrate pH6.0
p5TAT3 (Ser727) CST(#9134) 1:100 Sodium citrate pH6.0
pNFkB (Ser529) CST(#3037) 1:25 Sodium citrate pH6.0
pRB (Ser807/811) CST(#9308) 1:50 Sodium citrate pH6.0
pH2AX (Serl39) CST (#9718) 1:50 Sodium citrate pH6.0
pBRCAl (Serl524) CST(#9009) 1:25 Sodium citrate pH6.0
p-p53 (Serl 5) CST(#9286) 1:100 Sodium citrate pH6.0
Ki67 DAKO (M7240) 1:50 Tris-EDTA pH9.0
pHH3 CST(#9701) 1:100 Tris-EDTA pH9.0
Caspase 3 CST (#9661) 1:200 Sodium citrate pH6.0
Table 5.2. Antibodies used for pathway classification, concentrations, and
antigen retrieval conditions. Antigen retrieval was for 5minutes in a microwave
pressure cooker in all cases.
5.2.4 AQUA automated image analysis
A detailed description of the AQUA HistoRx methodology is available elsewhere
(178; 197). Pan-cytokeratin antibody was used to identify infiltrating tumour cells,
DAPI-counterstain to identify nuclei, and Cy-5-tyramide detection for target for
compartmentalised (tissue and subcellular) analysis of tissue sections.
Monochromatic images of each TMA core were captured at x20 objective using an
Olympus AX-51 epifluorescence microscope, and high-resolution digital images
analysed by the AQUAnalysis™ software. If the epithelium comprised <5% of total
core area, the core was excluded from analysis.
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5.2.5 Protein expression analysis and statistics
AQUA scores were averaged from replicate cores. Protein expression data were
analysed in Cluster v2.11 and visualised using Treeview vl.6, as previously
described (198). Raw AQUA scores were filtered so that >50% of protein expression
data was present for each tumour analysed. K-means clustering was performed on
filtered AQUA scores which had been log-transformed, normalised by protein, and
mean-centred. Overall survival was subsequently assessed by Kaplan-Meier
analysis with log-rank testing to determine statistical significance. To assess whether
our clusters provided more accurate predictions than standard clinicopathological
parameters, we performed univariate and multivariate analysis using Cox
proportional hazards regression models. Comparison of differences in means for
proliferation and apoptosis were performed using one-way ANOVA, and differences
in distribution of histological subtypes and grade per cluster by Chi-squared test. All
calculations and analyses were two-tailed where appropriate and done with SPSS
14.0 for Windows (SPSS, Inc., Chicago IL).
5.3 Results
5.3.1 Patient characteristics
Ovarian tumours were analysed from 168 patients. Of these, 152 patients had
sufficient AQUA data after filtering (>50% data present) for subsequent clustering
and survival analysis. Clinicopathological details for these patients summarised in
Table 5.1. For the whole group, the median overall survival from diagnosis was 42.9
months (range 0.8 - 161.0 months) and the 5 year overall survival was 19.0 percent.
5.3.2 Phosphoprotein expression and pathway activation is
heterogeneous within and between histological subtypes
We first sought to quantify and visualise the activation state of eight growth- or
survival-promoting pathways (PI3K, MAPK, [3-catenin, STAT, NFkB, ER, cell
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cycle, DNA damage response; Figure 5.1) by measuring the tissue expression of ten
phosphoprotein targets.
Cadheriri
Figure 5.1: Schematic of pathways investigated in this study.
Representative expression across different cancers is shown in Figure 5.2A and in the
same cancer in Figure 5.2B, in order to illustrate how the AQUA score relates to in




Figure 5.2: AQUA quantitative image analysis. (A) Representative
immunofluorescence images of each of the phosphoproteins and pathological
markers used within the study. Blue = DAPI nuclear counterstain, Green =
cytokeratin tumour mask, Red = target. (B) Representative staining from an
individual case, with corresponding AQUA score represented as both a heatmap and
whole integer.
Phosphoprotein expression was heterogeneous within (Figure 5.3A) and between
(Figure 5.3B) histological subtypes, indicating that similar subtype heterogeneity
exists at a functional, phosphoprotein level, to that recently reported for total protein
expression in ovarian cancer (191). When analysed for the most common (median)
expression difference between histological subtypes (Figure 5.3B), subtypes exhibit
differences in phosphoprotein expression and pathway activity. Thus serous
carcinomas exhibit relatively high expression of DNA-damage response
phosphoproteins (pBRCAl and pHistone-H2A.X) with low p53 phosphorylation,
while clear cell carcinomas show relatively high levels of phosphorylation of the
growth and cytokine dependent pathways (3-catenin, STAT, and NFkB and the
downstream tumour suppressor pRB. However, there are no significant differences in
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proliferation (measured by Ki67 and pHH3) or apoptosis (measured by activated
caspase 3) between the main histological subtypes (one-way ANOVA; Ki67
p=0.120, pHH3 p=0.066, activated caspase 3 p=0.056). These data suggest that
crossover exists between morphology and molecular phenotype in ovarian cancer,
but that re-classification of tumours by phosphoprotein signature may refine
prognostication and prediction by traditional histopathological parameters.
5.3.3 Regrouping of ovarian carcinomas by phosphoprotein profiling
reveals subgroups with distinct pathway activation profiles and
pathological properties
In order to determine the value of phosphoprotein profiling compared to traditional
histopathological subtyping, we used K-means clustering to organise the tumours on
the basis of phosphoprotein expression. Three main clusters were identified (Figure
5.3C). The distribution of histological subtypes in Figure 5.5 confirmed the crossover
between morphology and phosphoprotein expression. Cluster 1 contained a high
proportion of serous, endometrioid and mucinous carcinomas and cluster 2 a high
proportion of clear cell carcinomas. Cluster 3 contained predominantly serous and
mixed-histology tumours. Poorly differentiated tumours were distributed equally
across phosphoprotein clusters, but cluster 3 tumours had a lower proportion of well
and poorly differentiated tumours (Chi-squared test, p = 0.016). However, in contrast
to histopathological subtypes, phosphoprotein clusters showed significant differences
in proliferation and apoptosis (Figure 5.6), with cluster 3 showing significantly
higher proliferation (one-way ANOVA; Ki67 p=0.01, pHH3 p<0.0001) than clusters
1 and 2. Clusters 1 and 3 showed lower apoptosis measured by activated-caspase 3
(one-way ANOVA; p=0.044) than cluster 2. Each of the clusters also had distinct
profiles of pathway activation (Figure 5.4), with cluster 1 showing low level
expression of the markers analysed, cluster 2 high levels of phosphorylation of
hormone, growth factor and cytokine-dependent signalling pathways (ER, MAPK, |3-
catenin, STAT, NFkB) and p53, and cluster 3 activation of PI3K and DNA-damage
sensing proteins, but relatively low p53 phosphorylation.
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Figure 5.3: Visualisation and analysis of phosphoprotein expression data (1). (A
and B) Phosphoprotein expression by histological subtype (median expression levels
illustrated in (B)). K-means clustering of (C) produces 3 distinct phosphoprotein




















Figure 5.4: Visualisation and analysis of phosphoprotein expression data (2).
Pathway activation status of the three phosphoprotein clusters.
Cluster




Figure 5.6: Proliferation and apoptosis per phosphoprotein cluster. One-way
ANOVA; Ki67 p=0.01; pHH2 p=0.001; caspase 3 p=0.044.
5.3.4 Phosphoprotein profile clusters provide a novel predictive
framework for rationalising cancer therapies
Since phosphoprotein clusters differentially express pathway activation markers, we
sought to establish whether this approach could be used to predict responses to
existing therapy, and therefore potentially also novel therapies. Baseline assessment
of prognosis by univariate log-rank analysis for clinicopathological parameters
(Table 5.1) and phosphoprotein cluster showed that age, stage, grade, histology and
phosphoprotein cluster were all significantly associated with overall survival (Table
5.1 and Figure 5.7). Phosphoprotein cluster was associated with a hazard ratio (HR)
of 1.36 (95% CI 1.08-1.72). Survival by stage showed little difference between stage
I and II versus stage II and IV, similar to that recently described (191). Only stage
remained a significant predictor of overall survival in a multivariate Cox regression
model (p=0.011; HR = 1.34; 95% CI 1.06 - 1.69). However, we hypothesised that
since cluster 3 showed a pattern of phosphoprotein expression indicating high levels
of DNA-damage (high phosphorylation of BRCA1 and H2A.X) but an absent p53
response (low p53 phosphorylation) that tumours contained within this cluster would
be relatively insensitive to further DNA-damage induced by DNA-crosslinking
agents such as carboplatin and cisplatin. Given the relatively high rate of
proliferation rates of these tumours (Figure 5.6), they would nevertheless be expected
to be sensitive to spindle poisons such as taxanes. Subgroup analysis of patients
treated with platinum alone compared to a platinum and taxane-containing regimen
81
supported this hypothesis, with significantly poorer survival for patients in cluster 3
relative to clusters 1 and 2 when treated with platinum alone (Figure 5.8; p = 0.006;
HR = 1.46; 95% CI 1.11 - 1.92). In patients treated with taxane-containing regimens,
survival for cluster 3 tumours was equal to that of clusters 1 and 2. When adjusted
for chemotherapy, phosphoprotein cluster and pathological stage were the only two
variables which were significantly associated with survival by univariate analysis. In
a Cox regression model, only phosphoprotein cluster remained a significant predictor





Figure 5.7: Kaplan-Meier survival curves for significant variables (1). For the
whole cohort. P values = log rank test.
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Figure 5.8: Kaplan-Meier survival curves for significant variables (2). By




This study is the first to group human cancers based on the activation state of
oncogenic pathways by quantitative phospho-protein expression analysis. We chose
ovarian cancer as a model for this approach since the disease is proving resistant to
classification by existing approaches (such as gene expression array analysis)
(199;200) but there is some evidence to suggest that a few well characterised
pathways are aberrantly expressed in different histological subtypes (201). We have
shown that while phosphoprotein profiling does show some association with
traditional histopathological subtypes, reclassification on the basis of similar
phosphoprotein expression by cluster analysis reveals new molecular subgroups
which have distinct pathological characteristics in terms of cell fate (proliferation and
apoptosis) which are not apparent by histopathological classification alone. These
phosphoprotein clusters also provide a means to predict a priori which patients may
respond better to a particular therapy. In this case, the DNA-damage response profile
of excessive DNA damage (high pBRCAl and pH2AX) in the absence of p53
phosphorylation suggested relative resistance to platinum-based therapy, which was
borne out in subgroup analysis of chemotherapy regimens and multivariate analysis.
Therefore patients with cluster 3 tumours had a worse overall survival than cluster 1
or 2 tumours when treated with the DNA-crosslinking cytotoxics cisplatin or
carboplatin alone, but all three clusters had the same overall survival when treated
with a combination of cisplatin/carboplatin and a taxane mitotic spindle poison,
which might be expected to kill cells by p53-independent mechanisms such as
mitotic catastrophe. Additional therapeutic targets are PI3K inhibitors in cluster 3
and growth factor inhibitors (either alone or in combination) in cluster 2. Therefore it
might be reasonable to add a PI3K inhibitor or mTOR inhibitor to taxane-containing
regimens in patients with cluster 3 tumours in order to increase efficacy. Validation
of the clustering observed within this study within an independent cohort, and further
investigation in vitro and in vivo of the therapeutic targets identified herein, are
warranted.
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The finding of a DNA-damage response profile predictive of chemotherapy response
is in keeping with a growing body of evidence supporting the use of molecular
targets within DNA-damage and apoptotic response pathways as predictive tissue
biomarkers in ovarian cancer. p53, bcl2, MMR, ERCC1, and BRCA1 have all been
implicated in cisplatin resistance (202-207). For instance, BRCA1 plays a complex
role in mediating sensitivity and resistance to platinum-based therapies and taxanes,
and has been the subject of recent review (207). Functional BRCA1 is associated
with resistance to platinum and sensitivity to taxanes (207). No data exists on the in
vivo role of phosphorylated BRCA1, one readout of the function of BRCA1, in any
cancer, although the serine 1524 site measured in this study is known to be
phosphorylated in response to DNA damage in model systems (208). One
interpretation of the high pBRCAl (Serl524) in cluster 3 is that BRCA is functional
and can overcome platinum-induced damage. However, given the high p-histone
H2A.X expression (which when phosphorylated at serine 139 localises to sites of
DNA-damage (209)) and low p53 (Serl5, which is also phosphorylated in response
to DNA-damage (210)) pattern observed in cluster 3, we might postulate that DNA-
damage has already been sustained but downstream p53-dependent effector
mechanisms have failed, and that further DNA-damage is unlikely to trigger
apoptosis in a p53-dependent manner. Mutation of p53 (Serl5) is also known to
inhibit p53-dependent cisplatin-induced apoptosis (211). The relatively low rate of
apoptosis seen in cluster 3 is consistent with this hypothesis. Since taxanes mediate
much of their effect in a p53-independent manner, this explains the relative
sensitivity of cluster 3 to taxanes in line with previous data. In this way the
measurement of phosphoproteins can provide additional functional information about
key nodes in signalling pathways beyond that seen by total protein measurements
alone.
Our analysis of upstream signalling pathways has revealed potential new targeted
and combinatorial therapeutic options. In cluster 3 there is high expression of
activated AKT, which is a surrogate for PI3K pathway activation and may be a
candidate biomarker for RTK and mTOR inhibitors in breast and other cancers
(71 ;212). Similar biomarker data for ovarian cancer is lacking. An inverse
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relationship between pAKT and p53(Serl5) has been observed in vitro, and is
thought to in part mediate cisplatin-resistance via a p53-upregulated modulator of
apoptosis (PUMA)-dependent and p53-dependent mechanism (211), which lends
support to the inverse relationship between these proteins seen in this study. These
data suggest that the addition of a PI3K/mTOR inhibitor may be a novel combination
approach in ovarian tumours harbouring this signature in vivo.
Cluster 2 tumours show a phosphoprotein profile which is suggestive of growth-
factor dependency, with high levels of phosphorylation of pathways which are
known to connect extracellular growth signals from cytokines and growth factors
(pERK, (3-catenin, STAT, NFkB, ER; see figure 5.1) with cellular growth and
survival. Although data exists implicating these pathways in ovarian cancer
histogenesis, this is the first time that the activation state of these pathways measured
by phosphoprotein analysis have been described in clinical samples. Somatic
mutations of K-RAS (213-215) and CTNNB1 (the gene encoding |3-catenin) (216) are
seen in mucinous and endometrioid ovarian cancers respectively, and aberrant Wnt,
JAK/STAT and MAPK signalling has recently been described in serous ovarian
cancers by gene expression analysis (192). These data are not directly comparable
with phosphoprotein data, but the phospho-MAPK, [3-catenin, and STAT expression
seen in serous cancers is in keeping with deregulation of these pathways in a
proportion of serous cancers, further supporting the validity of the current approach.
More importantly, each of these pathways represent either existing or novel
therapeutic targets, and the pharmacologial agents which target them are relatively
low toxicity compared with cytotoxic chemotherapies. Good biochemical response
rates have been seen in tumours treated with aromatase inhibitors in phase II clinical
trials (217-219), and Wnt/P-catenin antagonists have shown promising efficacy in
vitro and are emerging as new therapeutic targets in cancer (220). Much less in
known about STAT signalling and ovarian cancer therapy, but one study suggests
therapeutic efficacy in vitro with the JAK inhibitor AG490 (221).
In conclusion, this part of the study is the first to measure the activation states of a
number of pathways by phosphoprotein analysis. This approach offers the
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opportunity to represent a sufficient amount of the disease complexity with a
relatively low volume of data. It identifies factors of importance in response
prediction to existing chemotherapies, but also several new hypotheses about novel
targets and approaches to individualised therapies. These findings will need further
validation in both experimental and clinical settings.
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Chapter 6: Describing Pathways (3): The systems pathology approach.
6.1 Introduction
In the preceding chapters we have extensively discussed the need for accurate
measurements so that biological data may be input into mathematical models, in
order to predict therapeutic response. In this chapter we use these principles and
populate a new mathematical model of RTK-signalling, developed in collaboration
with colleagues at the Centre for Systems Biology at Edinburgh, with data generated
using reverse phase protein arrays. We validate our findings in a clinical cohort using
quantitative protein expression measurements using AQUA image analysis.
As previously discussed, HER2-targeting receptor tyrosine kinase (RTK) inhibitors,
such as trastuzumab and pertuzumab, show clinical efficacy in breast and ovarian
cancer but measurement of HER2 protein expression or gene amplification status is a
poor predictor of response with a very low positive predictive value (157; 158).
Activating mutations in the oncogene PIK3CA and inactivation of the tumor
suppressor gene PTEN are known to regulate phosphotidylinositol 3-kinase signaling
and cell proliferation and survival pathways, and empirically these have been shown
to play a role in resistance to anti-HER2 therapies in breast cancer (71; 187).
However, the evidence supporting the role of PI3K-pathway activation in RTK-
inhibitor resistance has only been tested in very small cohorts of patients
retrospectively ((71) and (187), n=55 and n=47, respectively). Further evidence is
required in order to support the use of PI3K pathway biomarkers in the clinic
supported by robust preclinical and clinical evidence.
Kinetic (or dynamic) computational models offer the opportunity to cheaply and
efficiently test the efficacy of targeted therapies in silico (that is, computationally) as
part of the preclinical testing process (89). However, this methodology is still
perceived as esoteric and not clinically applicable because there are very few
successful examples of when such modelling has changed practice (66). In oncology,
systems biology has not yet made an impact, but the use of therapies targeted against
the products of cellular oncogenes in signalling pathways lends itself to this approach
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since these pathways can readily be modelled using ordinary differential equations
(89). To date, canonical pathways such as the epidermal growth factor receptor
(EGFR) pathway have only been modelled in order to explain and predict
physiological phenomena (102-108). However, such models have not been so helpful
for understanding therapeutic interventions, since they frequently fail to include
important oncogene and tumour suppressor nodes, which are known to be
fundamental to carcinogenesis and proven resistance proteins (such as HER2, PTEN,
and SRC in PI3K and MAPK signalling models).
The aim of this study was to address these deficiencies in current models by (1)
developing a new kinetic model which could be interrogated to predict resistance to
RTK-inhibitor therapies, and (2) directly test predictions in vitro and in clinical
samples.
6.2 Materials & Methods
6.2.1 Computational modelling
A kinetic model of heregulin-induced HER2/3 signalling through MAPK and PI3K
pathways was developed on the basis of the model proposed by Hatakeyama et al
(13). The whole kinetic model contains 56 ordinary differentials equations (ODEs)
(S1.1 )-(S 1.56) describing the change of the concentrations of 56 biological entities
(proteins, receptors, and lipid second messengers) involved in MAPK and PI3K
signalling (see 'Appendix C - mathematical model, ODEs'). A detailed modeling
methodology and description of the model design is given in B.l and B.2 (Appendix
B - modeling methods and description of mathematical model). The abbreviations
used in the text and ODEs are given in the 'Appendix C - mathematical model,
ODEs'. All network schemes were designed using the Edinburgh Pathway Editor
(222). The computer model construction, fitting and analysis were implemented
using the DBsolve package for kinetic modelling (223) and SimBiology modeling
software (MATLAB, The MathWorks Inc.). The model parameterisation procedure
permitted us to describe satisfactorily experiments of activation in the different
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branches of the ERK/AKT signalling network (see Figure S4 in 'Appendix D -
figures') and determine a set of kinetic parameters of the model (see Tables S2 and
S3 in 'Appendix C - mathematical model, ODEs').
6.2.2 Ceil Culture and Collection of Lysates
PE04 and BT474 cells were grown as monolayer cultures in DMEM supplemented
with 10% heat-inactivated foetal calf serum (FCS) and penicillin / streptomycin
(lOOIU/mL) in a humidified atmosphere of 5% CCF at 37°c. Time course
experiments were set up by plating cells into 10cm 0 petri dishes and leaving for
48hrs. Cells were then briefly washed in PBS before transferring to phenol red-free
DMEM containing 5% double charcoal-stripped serum supplemented with penicillin
/ streptomycin (lOOIU/mL) and glutamine (0.3mg/mL) for a further 48hrs prior to
treatment. Paired lysates were prepared by first treating relevant dishes with
pertuzumab (lOOnmol/L) +/- bpV(pic) (50nmol) immediately followed by the
addition of heregulin-(3 (lnmol/L). Samples were collected at time points of 1, 2, 5,
10, 30, 45 or 60 mins, washed in PBS, and immediately lysed in ice-cold isotonic
lysis buffer [50mM Tris-HCl (pH7.5), 5 mM EGTA (pH 8.5), 150 mM NaCl, 1%
Triton X-100] supplemented with aprotinin (10 pg/mL) and a protease inhibitor
cocktail (Roche, 11836153001). Lysates were centrifuged for 6 min at 13,000 x g
and protein concentrations of supernatants subsequently determined using the BCA
assay (Sigma, BCA-1). All cell culture and timecourse experiments were performed
at least three times, and representative RPPA and western blot curves were used for
the model fitting procedure described above and to validate model predictions.
6.2.3 Western Blotting
Protein lysates were electrophoretically resolved on either 10% or 12% SDS-PAGE
and transferred overnight onto Immobilon-P membranes (Millipore, Bedford, MA).
After transfer, membranes were blocked with 1% blocking agent (Roche; #1520709)
in TBS before probing overnight at 4°C with the appropriate primary antibody made
up in 0.5% blocking agent. Primary antibodies used for western blotting were as
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follows: anti-phospho-AKT (Ser473) (Cell Signaling Technology, #9271) at 1:1000;
anti-AKT (Cell Signaling Technology, #9272) at 1:1000; anti-phospho-p44/42 MAP
Kinase (Thr202/Tyr204) (Cell Signaling Technology, #9101) at 1:1000; anti-p44/42
MAP Kinase (Cell Signaling Technology, #9102) at 1:1000; anti-HERl (Cell
Signaling Technology, #2232) at 1:1000; anti-HER2 (Cell Signaling Technology,
#2242) at 1:1000; anti-phospho-HER2 (Tyr877) (Cell Signaling Technology, #2241)
at 1:1000; anti-HER3 (Cell Signaling Technology, #4754) at 1:1000; anti-phospho-
HER3 (Tyr1289) (Cell Signaling Technology, #4791) at 1:1000; anti-HER4 (Cell
Signaling Technology, #4795) at 1:1000; anti-PI3K (Cell Signaling Technology,
#4249) at 1:1000; anti-PTEN (Cell Signaling Technology, #9552) at 1:1000; anti-
phospho-PTEN (Ser380/Thr382/383) (Cell Signaling Technology #9554) at 1:1000.
Immunoreactive bands were detected using enhanced chemiluminescent reagents
(Roche; 1520709) and Hyperfilm ECL film (GE Healthcare, UK). Bands were
scanned using an Epson Perfection 4990 scanner and Integrated Optical Density
(IOD) absorbance values were obtained by densitometric analysis using Labworks
gel analysis software (UVP Life Sciences, Cambridge, UK).
6.2.4 Reverse phase protein arrays (RPPA)
Denatured and reduced protein lysates were spotted onto nitrocellulose-coated glass
slides (Eurogentec, Hampshire, UK), as previously described (224). Three replicates
were spotted per sample in eight two-fold dilutions. Slides were hydrated in
Whatman wash buffer for 5 minutes, Li-Cor blocking buffer for 1 hour (LI-COR
Biosciences, Nebraska, USA), and then incubated with primary antibodies overnight
at 4°c in a sealed box containing a damp paper towel. The following day slides were
washed in PBS/T at room temperature for 5 minutes (x3) before incubating with far-
red fluorescently-labelled secondary antibodies diluted in Li-Cor Odyssey Blocking
Buffer (lpL/2mL) at room temperature for 45mins with gentle shaking. Slides were
then washed in excess PBS/T (x3) / PBS (x3) and allowed to air dry before reading
on a Li-Cor Odyssey scanner at 680nm and 780nm and images exported as TIFF
files for further analysis. Slides were stained using the above primary antibodies
(matched total and phosphoproteins duplexed on each slide).
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RPPA analysis was performed using MicroVigene RPPA analysis module
(VigeneTech, Carlisle, MA, USA). Spots were quantified by accurate single
segmentation, with actual spots signal boundaries determined by the image analysis
algorithm. Each spot intensity was quantified by measuring the total pixel intensity
of the area of each spot (volume of spot signal pixels), with background subtraction
of 2 pixels around each individual spot. The mean of the replicates was used for
normalization and curve fitting. Curve fitting was performed using five parameter
logistical non-linear regression using a joint estimation approach ('supercurve
method'). The quantification yO (intensity of curve) or rsu (relative concentration
value) of sample dilution curves were normalized by corresponding total protein.
6.2.5 PIK3CA mutation analysis and copy number quantification
PIK3CA mutation analysis was performed using the ARMS/Scorpions multiplexed
PCR assay as previously described (225) to detect the four most common mutations
in PIK3CA, (H1047L, H1047R (Exon 20), E545K and E542K (Exon 9)). PIK3CA
copy number quantification was performed with primers for PIK3CA and the
glucokinase (GCK) gene as the reference gene as previously described (226).
Quantitative PCR was performed on the Rotor-Gene 6000 real-time detection system
(Corbett Life Sciences, USA), in 15|il reaction volumes containing 2x Power SYBR
Green PCR Master Mix (Applied Biosystems, USA) and l|lM forward and reverse
primers. PCR conditions were 10 m at 95°C followed by 40 cycles consisting of 10 s
at 95°C, 15 s at 60°C and 20s at 72°C. ACt was calculated as GCK Ct - PIK3CA Ct
and ACt>3 was defined as amplified.
6.2.6 Samples and tissue microarray construction
The population characteristics of the trastuzumab-treated cohort is summarised in
Appendix A. HER2 gene amplification status was confirmed by fluorescence in situ
hybridisation (DAKO HER2 FISH PharmDx, Ely, Cambridgeshire). The study was
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approved by the Lothian Research Ethics Committee (08/S1101/41). Following H&E
sectioning of representative tumour blocks, tumour areas were marked for TMA
construction and 0.6mm' cores placed into 3 separate TMA replicates for each
sample, as previously described (177).
6.2.7 Immunofluorescence
Immunofluorescence for PTEN was performed using methods previously described
(123). Briefly, 3pm tissue microarray slides were deparaffinized and antigen-
retrieved by pressure-cooking in 0.15mM sodium citrate buffer at pH6. Endogenous
peroxidases were blocked with 2.5% hydrogen peroxide for 15 minutes and non¬
specific binding blocked with serum-free protein block for 15 minutes. Slides were
then incubated with primary antibodies diluted in 0.025% PBST for 1 h at room
temperature (AE1/AE3 mouse monoclonal cytokeratin antibody, rabbit polyclonal to
PTEN (Cell Signaling) diluted 1:100 and 1:25 respectively. After washing in 0.025%
PBST sections were incubated for 1 hour at room temperature with secondary
antibodies, which included an Alexa 488-conjugated goat anti-mouse antibody
diluted 1:100 in 0.1M TBS, and prediluted goat anti-rabbit antibody conjugated to a
horseradish peroxidase-decorated dextran-polymer backbone (EnVision, Dako).
Slides were then incubated for 10 minutes with Cy5-tyramide, which is activated by
horseradish peroxidase, to visualize HER2 expression. 4',6-Diamidino-2-
phenylindole (Molecular Probes, Eugene, Ore) was used to stain the nuclear
compartment.
6.2.8 AQUA automated image analysis
A detailed description of the AQUA methodology is available elsewhere, and has
been described above (123). Pan-cytokeratin antibody was used to identify
infiltrating tumour cells and normal epithelial cells, DAPI-counterstain to identify
nuclei, and Cy-5-tyramide detection for target (PTEN) for compartmentalised (tissue
and subcellular) analysis of tissue sections. Monochromatic images of each TMA
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core were captured at x20 objective using an Olympus AX-51 epifluorescence
microscope, and high-resolution digital images analysed by the AQUAnalysis
software. Briefly, a binary epithelial mask was created from the cytokeratin image of
each TMA core. If the epithelium comprised <5% of total core area, the core was
excluded from analysis. Similar binary masks were created for cytoplasmic and
nuclear compartments based on DAPI staining of nuclei. PTEN expression was
quantified by calculating the Cy5 fluorescent signal intensity on a scale of 0-255
within each image pixel, and the AQUA score generated by dividing the sum of Cy5
signal within the epithelial mask by the area of the cytoplasmic compartment.
6.2.9 Statistical analysis methods
AQUA scores were averaged from replicate cores. In order to reduce type I error
which can result from using the minimum p-value method for determining the
cutpoint value for PTEN expression in Kaplan-Meier analysis (180), we utilised X-
Tile, which allows determination of an optimal cutpoint while correcting for the use
of minimum P statistics (179). Two methods of statistical correction forthe use of
minimal P approach were used, the first calculation of a Monte Carlo P-value and for
the second, the Miller-Siegmund minimal P correction (180). Overall survival was
subsequently assessed by Kaplan-Meier analysis with log rank for determining
statistical significance. Relative risk was assessed by the univariate and multivariate
Cox proportional hazards model. Comparison of PTEN expression class with
the clinical and pathological variables (age, tumour and nodal stage,
histological grade, ER and HER status, NPI) were made using X'2 analysis.
Comparison of differences in means in vitro were performed using the Student's T-
test. All calculations and analyses were two-tailed where appropriate and done with
SPSS 14.0 for Windows (SPSS, Inc., Chicago IL).
6.3 Results




In order to systematically assess resistance factors to anti-receptor tyrosine kinase
(RTK) therapy in cancer biopsies, we developed a kinetic mathematical model of
MAPK/PI3K signalling and used it to predict consequences of anti-HER2
monoclonal antibody therapeutic intervention (a full kinetic mathematical model
description is given in Appendix B - modeling methods and mathematical model
description). We developed it to describe HER2-inhibitor antibody/receptor binding,
HER2/HER3 dimerisation and inhibition, AKT/MAPK crosstalk, and the kinetic and
regulatory properties of PTEN (Figure 6.1 and Appendix D - figures S1-S3, S10).
The design of our model was also based on modelling studies of the HER signalling
network (105; 109;227;228). The inclusion of the tumour suppressor protein PTEN
was deemed particularly important since it is a key negative regulator of the PI3K
signalling pathway (229), and it has been implicated as a resistance mechanism to
trastuzumab in breast cancer (71; 187); however, the effect of quantitative decreases
in protein expression, which is more commonly seen than mutation or epigenetic
regulation, is unknown. The new model, including a PTEN subsystem, explicitly
describes the competition between the lipid and protein phosphatase activities of
PTEN, autodephosphorylation, and the balance and interchange between the active
(PTEN) and inactive (pPTEN) forms of the protein, using experimentally derived













Figure 6.1: Network schema of MAPK and PI3K signalling, a, Schematic
representation of mathematical model used to interrogate sensitivity and resistance
factors to RTK-inhibitors. The whole kinetic model contains 56 ordinary differential
equations and is described in detail in the Appendix B. Abbreviations used within the




Figure 6.2: Computational model validation and predictions. Time-course plots
of experimental data used to parameterise the computational model. Data were
generated from reverse phase protein arrays (phosphoprotein normalised by total
protein) and are representative of multiple experiments (heregulin-(3 (blue) and
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Figure 6.3: The theoretical dependence of therapeutic resistance R80 on the
ratio y of PTEN and PI3K*. (y = PTEN/PI3K*, see Appendix B for details). The
index of therapeutic resistance (R) was defined as follows: R80 = pAKT80/ pAKTO,
where pAKT80 - the value of pAKT signal when 80% of RTK receptors are
inhibited by the drug, pAKTO - pAKT signal in the absence of any RTK inhibitors.
The value of pAKT signal was taken at 60th min after HRG stimulation. Thus R
reflects the non-responsiveness (or resistance) of the pAKT signal to the inhibition of
receptors by RTK inhibitors. When R80=l the resistance is the highest, that means
that 80% inhibition of RTK causes no inhibition of pAKT signal. In our model high
resistance is observed on decreasing y3-5 times regarding to yo set in the model. The
value yo=105 corresponds to our theoretical results of 80% inhibition of pAKT signal
in response to 80% inhibition of RTK. Lower panels, Predicted effect of PTEN loss
on pAKT kinetics (left) in the presence or absence of pertuzumab, and resulting
experimental data (right),
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Figure 6.4: Comparison of computational predictions and unseen experiments
of steady-state levels of pAKT at 30 minutes. Kinetic and steady-state profiles of
pAKT by inhibition of PTEN function with bpV(pic) closely match computational
simulations.
The kinetic model (Figure 6.1 and submodels shown in Appendix) was then fit to
high-resolution in vitro dynamic phosphoprotein expression generated from reverse-
phase protein arrays and normalised to total protein expression (Figure 6.2), as well
as supportive western blot data Figures in Appendix D: SI2, SI3). Timecourse data
were generated from PE04 ovarian cancer cell lines stimulated with heregulin-|3 in
the presence or absence of the HER2 dimerisation-inhibitor pertuzumab (Figure 6.2
and Appendix D - Figure SI2), in order to derive kinetic parameters, as described in
Appendix B - modeling methods and description of mathematical model. Additional
timecourse profiles of BT474 breast cancer cell lines were studied, but not used for
parameterization of the mathematical model, in order to establish qualitative
similarities between cell lines and the generality of the approach. Additional model
validation was provided by heregulin dose-response experiments (Appendix D -
Figure SI3). The model satisfactorily reproduced the response kinetics of
heterodimerisation of HER2/HER3, pERK, and pAKT activation stimulated by
heregulin-(3, and the inhibitory effect of pertuzumab. A dominant signalling effect
through PI3K with sustained steady-state changes in PI3K signalling in response to
heregulin-(3 after 1 hour in multiple cell lines was observed (Figure 6.2).
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6.3.2 Resistance factor y dictates sensitivity and resistance to RTK-
inhibitor therapy
In order to predict which pathway components most influence therapeutic resistance
to anti-HER2 therapy, we used the kinetic model to interrogate which parameters
most influenced downstream pathway activation in response to endogenous ligand
stimulation and inhibition with dimerisation inhibitors. Computational analysis of the
model showed that HER2 receptor levels, total PTEN levels, and activation of PI3K
by mutation led to dimerisation inhibitor resistance measured by sustained AKT
phosphorylation after treatment with the dimerisation inhibitor pertuzumab
(Appendix D - Figure SI5); however, since the activation of PI3K required to induce
resistance was supraphysiological (xlO required to induce resistance in simulations
vs x2 activation by mutation as seen in vitro (230)), and patients are always selected
on the basis of high HER2 expression for receptor tyrosine kinase inhibitor therapy,
we focussed on PTEN as potential resistance mechanisms in order to offer a
quantitative explanation for therapeutic resistance observed in vivo (71). PTEN exists
in a signalling cycle with PI3K, such that the balance between the activities of PTEN
and PI3K enzymes, PTENmotivated PI3K (integrated resistance factor y; Figure 6.3
and Appendix B - modeling methods and description of model B.3) dictates the
sensitivity of AKT activation to ligand stimulation or inhibition. High y result in
effective inhibition of AKT activation in response to pertuzumab, while low y predict
sustained AKT activation and insensitivity to pertuzumab (Figure 6.3). Thus we
found that the resistance to inhibition is strongly y dependent. At low y the system
amplifies small signals from membrane receptors and becomes insensitive to
receptor inhibition. In Figure 6.3b this regimen corresponds to high values of the
therapeutic resistance index Rsofy)- In the range of y0 (corresponding to the
computational results in Figure 2a) signal transduction through PI3K/PTEN cycle is
sensitive to inhibition by pertuzumab (pAKT signal can be inhibited by 30-70%).
Further increase in y (more than ten times higher than y0) leads to strong inhibition of
pAKT signals due to significant weakening the signal transduction through the
PTEN/PI3K cycle (see Appendix B - modeling methods and description S3). Our
results are in a good agreement with ultrasensitive and signal-transducing regimes of
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signalling cascades described earlier for covalent modification (231 ;232) and kinase-
phosphatase cycles (233).
6.3.3 Computational simulations are predictive of unseen experiments
of therapeutic resistance caused by resistance factor y.
We tested the effect of changing the PTEN:PI3K ratio by stimulating with heregulin-
P after pre-treating PE04 cell lines with bpV(pic), a potent and specific inhibitor of
PTEN which acts by binding to the active phosphatase CX5R motif (234;235). The
model was entirely predictive of these unseen in vitro experiments, with dynamics
(compared by curve comparison and integration of kinetic profiles) and steady-state
levels of pAKT activation matching computational simulations, and abrogating
inhibition of pAKT with pertuzumab (Figure 6.4). Likewise, increasing the ratio of
PTEN:activated PI3K with the PI3K inhibitor LY294002 resulted in dose-dependent
inhibition of pAKT, but not pERK, in PE04 cells (Appendix D - Figure S14). This is
also in agreement with our theoretical results (see Appendix B - modeling methods
and description B.3). Therefore, the model suggests that resistance to RTK inhibitors
is dependent on the quantitative balance of both the protein expression of PTEN
(which is common in breast cancer (85)) and PI3K activating mutations, which are
commonly amplified and mutated in many breast and ovarian cancers (236;237).
6.3.4 The resistance factor y dictates resistance to pertuzumab in
cellular models in vitro.
Further validation of the capacity of measurement of PTEN:activated PI3K ratio to
predict therapeutic response was sought from cellular models of therapeutic
sensitivity and resistance. We measured total PTEN, PI3K mutation status of the four
most common mutations in the PIK3CA gene (H1047L and H1047R in exon 20,
E545K and E542K in exon 9, representing -90% of PIK3CA mutations) and PI3K
amplification status in a panel of 13 ovarian carcinoma cell lines to investigate the
association of PTENmotivated PI3K with response to pertuzumab (Figure 6.5a).
Total PTEN protein expression levels were strongly negatively correlated with both
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pAKT and percentage growth inhibition with pertuzumab (Pearson's correlation
coefficient 0.68 and 0.74 respectively; Figure 6.5b).
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Figure 6.5: Quantitative PTEN protein expression is associated with
pertuzumab sensitivity in vitro and trastuzumab resistance in vivo, a and b The
relative sensitivity of 13 ovarian carcinoma cell lines to the HER2 dimerisation
inhibitor pertuzumab was determined by growth assay (SRB), and expression of
PTEN and other MAPK and PI3K pathway components assessed by semi¬
quantitative western blotting. Sensitivity to pertuzumab is closely correlated with
PTEN expression but not with other pathway members, c, (left panel) AQUA
fluorescent analysis of PTEN expression in a tissue microarray core, showing
cytoplasmic localisation of PTEN (red) and masking of tumour areas for quantitation
by cytokeratin (green), (middle panel), Calculation of optimal cutpoint for PTEN
expression. X-tile calculates all possible combinations of results for different
cutpoints (upper panel) and corresponding relative risks (lower panel). Cutpoint is
selected on the best corrected and Monte-Carlo p-value. (right panel), Kaplan-Meier
survival curves for patients treated with trastuzumab for low (blue) and high (red)
protein expression of PTEN. Overall survival is calculated from time of initial
diagnosis to date of death.
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Two of the cell lines, SKOV3 and OAW42, showed activating mutations in PI3K but
none of the cell lines harboured PIK3CA amplifications. Activation by mutation was
assumed to increase the activity of PI3K twofold (230), and calculation of
PTEN:activated PI3K resulted in small increases in correlation coefficients with
pAKT and growth to 0.73 and 0.76 respectively, suggesting that PTEN expression is
the dominant factor in sensitivity to HER2 dimerisation inhibition, consistent with
recent reports (238), and the relatively weak effect of x2 activity of PI3K on
resistance seen in simulations. However, measurement of HER 1-3, pAKT, or pERK,
were not highly correlated with sensitivity to pertuzumab (Figure 6.5b).
6.3.5 The quantitative expression of PTEN is associated to trastuzumab
resistance in the clinic.
Since both computational and cellular modelling strongly suggest that quantitative
PTEN protein expression most influences ultimate cellular response to HER2
inhibition, we quantified expression of PTEN in 122 trastuzumab-treated primary
breast tumours using the AQUA quantitative image analysis system (Figure 6.5c and
Appendix A) on primary breast tumours arrayed on tissue microarrays. Increasing
PTEN expression was proportional to decreased relative risk of death when treated
with trastuzumab (Figure 6.5c, middle panel), mirroring the effect on the therapeutic
resistance index Rso(y) by changes in y. A rigorously defined cutpoint for PTEN
expression (see materials and methods) resulted in a mean reduction in overall
survival of 21.6 months in PTENlow vs PTENhlgh patients (Figure 6.5c; uncorrected
p=0.0003, Miller-Seigmund p=0.0099, Monte Carlo p=0.01), equivalent to a 3.0
times increase in relative risk of dying from breast cancer after treatment with
trastuzumab in PTENlow cases (RR = 3.0; 95% CI 1.6-5.5, p<0.0001). In univariate
analysis, tumour size, ER status, chemotherapy regimen, and PTEN expression levels
were all associated with significant survival differences (log-rank test, p<0.05,
Appendix A), but PTEN remained the only significant predictor of survival in
multivariate analysis (Cox logistic regression, p=0.01) and corresponds well to the
parameter y when PI3K expression level assumed to be constant. HER2 expression
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and PIK3CA mutation status (mutations found in 26/119 (21.8%) available samples)
were not predictive of survival.
6.4 Discussion
Our data has shown the successful application of kinetic modelling of the PI3K and
MAPK signalling pathways in the selection of resistance factors to RTK-inhibitors.
We have shown that PTEN is the dominant resistance factor to RTK-inhibition. As
far as we are aware, this is not only the largest series of breast cancers treated with
trastuzumab to be analysed for PTEN to date, but the first to demonstrate strong
association of the level of PTEN expression with overall survival rather than simply
time to progression (71). Our data strongly suggest that PI3K inhibition in PTEN-low
tumours should be combined with RTK-inhibitors, as recently shown for lapatinib in
vitro (239). Similar to quantitative ER positivity in breast cancer (240), our data
show that approximately a quarter of HER2+ patients may be spared ineffective, and
potentially toxic, treatment if stratified by PTEN expression.
The phosphoinositol 3-kinase (PI3K) pathway mediates key hallmarks of cancer such
as growth, proliferation, survival, motility and angiogenesis (186). PI3K
phosphorylates the lipid second messenger PI, which recruits AKT and PDK1 to the
cell membrane. PTEN is a key negative regulator of the PI3K signalling pathway
(229). PTEN mutations are responsible for the hereditary diseases Cowden disease,
and partial loss-of-function mutations or loss of heterozygosity (LOH) are common
in the majority of cancers, and loss of expression by techniques such as
immunohistochemistry or Western blotting is frequently seen. Although recent
reports have suggested that PIK3CA mutations are important on a PTEN mutant
background (241), and PTEN expression may cooperate with PIK3CA mutations in
breast cancer and mediating trastuzumab resistance (71;238), our data show that
PTEN exerts dominant control in downstream pathway activation and resistance to
RTK-inhibitors. PIK3CA mutations exert a relatively small influence on PTEN:PI3K
signalling cycle and resistance, and would have to have a five-tenfold increase in
enzymatic activity to mediate resistance, which explains the lack of effect of PIK3CA
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mutation on trastuzumab resistance seen herein. Previous reports implicating
PIK3CA mutations in HER2-inhibitor resistance have only been in vitro or are very
small cohorts of patients (71; 187). Other RTK inhibitors such as pertuzumab have
also been shown to inhibit PI3K pathway activation (242;243) suggesting that
constitutive activation of this pathway through PTEN downregulation may also
contribute to pertuzumab resistance in vitro and in vivo. Given the quantitative nature
of these phenomena, a mathematical description and systems analysis of the PI3K
pathway has been useful for understanding therapeutic responses, and allow better
selection of patients expected to respond to receptor tyrosine kinase inhibitors.
In this chapter, we have successfully demonstrated how a systems biology approach
can generate hypotheses that can be tested experimentally in preclinical models and
which can then be applied to clinical evaluation. Predictions from this model are
consistent with known findings, have been extended within this study, and add
weight to the use of PTEN as a biomarker for stratifying patients for HER2-inhibitor
or combinatorial therapy, particularly an RTK-inhibitor and PI3K-inhibitor in
cancers with low y. This model provides a foundation for further development and
inclusion of more variables that may impact on RTK inhibitor response. Network
topology, kinetics, and quantities of molecules dictate cellular, and ultimately clinical
outcome. Systems biology approaches, in particular deterministic kinetic models
based on experimental data, offer a new approach for integrating molecular
pathology and computational modelling in order to more rationally interrogate cancer
pathways and predict responses to therapy.
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Chapter 7: Conclusions and future directions.
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7.1 Conclusions and future directions.
In the preceding chapters we have discussed some of the challenges facing
translational scientists in the discovery, testing, and validation of tissue biomarkers in
order to predict therapeutic responses in cancer patients. Over the past few years
these challenges have been addressed largely by academic oncologists, often in
breast cancer research which has, above all other solid cancer research, been driven
by effective campaigning, funding, public awareness, and patient advocacy.
However, the reality has been that the selection of patients for the right therapy at the
right time has fallen short of expectations, as demonstrated by only small gains in
survival and the slow adoption of new tests into the clinic. Many other cancers, such
as ovarian and pancreatic cancer, still have a dismal prognosis. Too many patients
still receive unnecessary, and toxic, therapies.
We propose that systems biology approaches may be a fruitful avenue for preclinical
testing of biomarkers, which may complement existing experimental approaches. In
doing so, we have highlighted how accurate quantification of proteins in tissues is
required to populate mathematical models; a by product of this has been that we have
developed new, systematic approaches to interrogating pathways and visualising
molecular pathology data (ovarian cancer classification), and have used dynamic
timecourse experiments to try and understand how static measurements in pathology
relate to dynamic cellular processes (Sprouty 2 in breast cancer). We have used new
image analysis technologies to advance more traditional biomarker approaches (Ariol
for ER and PR immunohistochemistry quantification in existing clinical trials), and
also to investigate novel approaches to biomarker testing and discovery (AQUA for
ovarian cancer classification and quantitative PTEN expression). We have started to
explore new technologies such as RPPA for high throughput, high accuracy
quantification. While molecular pathology sits at the heart of these endeavours they
are, by their very nature, multidisciplinary, and require the concerted efforts of teams
of professionals beyond those usually associated with biomedical research. In
addition to hopefully advancing translational science, the type of multidisciplinary
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work described herein can also be a hugely intellectually rewarding, and satisfying
experience.
The work described leaves numerous avenues for future research and development.
There is no shortage of targeted therapies for which a systems biology approach may
usefully be applied and models developed. We have already proposed that Sprouty
should be integrated into our existing model so that our findings can be tested in
silico. This would also be a first step in including gene expression events in kinetic
models, such that signalling processes are not restricted to phosphorylation events
alone. Another immediate advance would be the addition of mTOR signalling to our
PI3K model already developed, since these agents (such as Everolimus, RAD001)
are already entering Phase III trials but show uncertain, and sometimes disappointing
clinical responses. However, this remains a reactive approach and the real test of
systems biology will only come when a new marker or agent not already in late
development is tested prospectively by experimentation or in early phase clinical
trials. It is likely that systems biology will not be the only evidence but complement
biochemical, in vitro and in vivo data to determine whether a particular therapy,
combination of therapies, or marker warrants further work or investment.
From a clinicopathological standpoint, the further evidence that PTEN predicts
response to trastuzumab, over and beyond HER2 expression, is compelling evidence
that a clinical test for PTEN should be developed for the clinic. Further validation of
the AQUA cutpoint determined in our study needs testing in an independent cohort
of patients, and in the context of an appropriately powered prospective clinical trial.
In order to develop a suitably robust test which would show sufficiently low inter-
laboratory variation, standards need to be developed which can be measured along
with the clinical samples in order to control and normalise fluorescence intensities.
These standards might take the form of known cell line standards, or recombinant
proteins. The HERA translational study (investigating adjuvant trastuzumab in early
breast cancer) may provide an opportunity for PTEN validation. Since some patients
still derive benefit from trastuzumab even with low PTEN expression, it is unlikely
that treatment would be withheld in these patients. They might, however, be
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excellent candidates for combined therapy with a PI3K inhibitor, and further
preclinical and clinical testing of this hypothesis should be pursued.
The exploratory study on ovarian pathway classification has resulted in a number of
new hypotheses to test for combinatorial therapy and response prediction, and the
approach can be applied to any cancer. The findings of the study require validation in
an independent cohort of ovarian tumours, and this experiment is currently
underway. However, we advocate a more systematic approach to pathway profiling
than that described herein, which was candidate-driven, rather than based on primary
experimental data. Instead of selecting pathways and markers from the literature, in a
follow-on experiment designed to pathway profile breast cancers, we have used
phospho-protein antibody arrays (Eurogentec, Hampshire, UK) to profile 250
phospho-epitope targets spanning thirteen pathways in a panel of breast cancer cell
lines. Unsupervised analysis of these data has resulted in regrouping of the cell lines
into three clusters with distinct pathway phospho-activation profiles, which are






















These profiles are being validated in a large cohort of breast cancers (n=500) by
AQUA and RPPA analysis, and therapeutic targets tested in vitro in the same cell
lines. A similar set of data is also being generated in ovarian cancer cell lines, in
order to establish in vitro models in which combinatorial regimens may be tested.
Finally, systems biology is a nascent field which has been hyped as the solution to a
panacea of ills, from inefficient drug design to famine, but has (quite rightly) yet to
gain wide acceptance within clinical medicine. The hype has not been matched with
success, partly due to unrealistic expectations. In order for the field to continue and
become more clinically relevant, all stakeholders (for instance pathologists,
oncologists, pharmaceutical companies, biologists, and funding agencies) require
education in systems biology, multidisciplinary approaches, and the opportunities
and limitations that systems biology has to offer. Together with real clinical success
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A.1 Patient characteristics of trastuzumab-treated cohort.








































Appendix B: Modeling methods and description of mathematical model.
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B.1: Modeling methods
The parameter set of the model contains 82 kinetic parameters of enzymes and
receptors with 15 initial concentrations of proteins/metabolites. A direct attempt to
use a model parameter set obtained from existing models (103) to describe our
experimental data did not yield satisfactory results, which was not unexpected since
different experimental models can yield different model parameters
(103;105;244;245), as seen in other models of MAPK signalling ((103; 105;244-247)
and Table S2 in Appendix C - mathematical model, ODEs). Also, determination of
the model parameters of signalling networks are subject to uncertainty and non-
identifiability of kinetic parameters of the enzymes involved in signalling (244-246).
We therefore carried out parameter fitting of the model to experimental data obtained
on the human carcinoma cell line PE04.
In the fitting procedure we used kinetic experimental data on phosphorylation of
HER2, AKT, ERK, and PTEN obtained in the absence and presence of pertuzumab.
As an initial approximation of the model parameters we used the parameter set from




Ylexp)(t ) Y"h) (t )
where ij v k' and ij v k' - experimental and theoretical data on concentrations
of pHER2, pERK, pAKT, pERK (/= 1.. .4), obtained in the absence and presence of
pertuzumab (/'= 1,2) at time points tk = 1, 2, 5 10, 20, 60 minutes (k= 1, 6) after
T(exp)(r ) Y(,h) (t )
heregulin-(3 stimulation. ij ^ *' and ij x '"'were normalised to their maximal
values.
To identify all parameters we used a semi-automatic technique which involved
model decomposition, sensitivity analysis, and minimization of cost function (223).
According to the model decomposition method (247) we used sensitivity analysis




contributing significantly to '' v k'. The results of sensitivity analysis (see Fig.
S5-S9 in Appendix D - Figures) showed that the main contribution to pHER2
kinetics are made by the reactions of the binding of HER3 with heregulin-(3 and
HER2/HER3 heterodimerisation followed by autophosphorylation of tyrosine
residues (see reactions V|i5i, V2,53, V3, V4 in main text Figure 1). Therefore, our first
stage of optimization was the parameters of the reactions included in this subsystem.
Most of the parameters were found to be close to the ones from (103; 105) (see Table
S2 in Appendix C - mathematical model, ODEs). To estimate the affinity of
heregulin-(3 to HER2 we took into account the dose-dependence of pAKT to
heregulin-(3 (see comparison simulation results with experimental data in Figure S13
in Appendix D - Figures).
The main contribution to pERK kinetics were, as expected, made by the
RAS/RAF/MEK/ERK branch of the network. The second stage of parameterization
procedure identified kinetic parameters involved in this subsystem. The third stage
used pAKT and pPTEN timecourse data to identify parameters of PI3K/PTEN/AKT
branch. We then identified parameters of the crosstalk between
RAS/RAF/MEK/ERK and P13K/PTEN/AKT branches (kinetic parameters of PP2A
phosphatase and feedback inhibition of RAF by active AKT), using the experimental
data obtained in the absence and presence of RTK inhibitor, pertuzumab. To
estimate kinetic parameters of the binding of pertuzumab with HER2 we also
considered experimental data on the dissociation constant of pertuzumab (248).
We next carried out local time-dependent sensitivity analysis (249) by calculating
Ym(t)
sensitivity of the observable variables ' v ' (such as pHER2, pAKT, pERK, and




where t - time after HRG simulation, P - set of model parameters involving the set
of kinetic parameters K=ki...kn and initial concentrations X0=xFig. S5-S9
S (t P I)
(Appendix B - methods) represents the values of sensitivity y ' ' at t=5
minutes for parameters contributing significantly in the observable variables.
139
B.2 Development of a kinetic model for simulation of RTK-inhibitor
therapy
We adjusted and further developed the model of ERK/AKT signalling pathways
proposed by Hatakeyama et al (103) in order to model heregulin-D and the RTK-
dimerisation inhibitor effects of pertuzumab on the human ovarian carcinoma cell
line PE04. We introduced the following modifications to the model in order to obtain
a set of kinetic parameters:
Ligand/receptor and receptor/receptor interaction
We generalized the model (103) to describe HER3/HER2 heterodimerisation
(reactions V2 and V53 in Fig. 1). We omitted HER3/HER4, HER4/HER4, and
HER2/HER4 complexes because there was very little detectable HER4 in PE04 cell
lines (Appendix D: Fig. SI6).
To describe the effect of pertuzumab on signal transduction in the ERK/AKT
pathways we introduced the binding of pertuzumab to HER2 (reactions V49 and V50).
We introduced a two-step mechanism of heregulin/pertuzumab binding with
receptors as well as heterodimerisation of HER3/HER2 (see Fig. SI, S2) in order to
reach good agreement between the model and experimental kinetics of the
HER3/HER2 dimerisation in the presence of the HER2 inhibitor. In contrast to a one
step mechanism (action mass reaction rate), two-step (or multi-step) binding of the
ligand to receptor proceeds through the reversible formation of ligand/receptor
complexes followed by formation of tight ligand/receptor complexes (247;250).
We normalised receptor and pertuzumab concentrations to the cytosolic volume of
the cell, which is necessary for conforming concentrations in different compartments.
The reactions occur in the receptor compartment (cell surface) and further
downstream signalling processes in the intracellular compartment (cytoplasmic
volume). The coefficient is V„,/Vc , where Vm= average volume of incubation
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medium per cell and Vc = cytoplasmic volume (227). In our experiments there are
105 cell/ml, therefore Vni=10~5ml, assuming Vc=3 10~9 ml, Vm/Vc=3000.
The following approximations were made in the model. We did not consider the
growth of cell population, gene regulation, or receptor synthesis in the model. We do
not include additional biosynthesis of PI in response to its consumption (251) and
propose the pool of the lipid second messenger PI to be constant during signal
transduction. These assumptions have been made because of the relatively slow rate
of these processes in comparison with signal transduction.
To model the effects caused by the loss of PTEN activity we added in the model the
reaction of PTEN inhibition by bpV(pic) (reaction 57). Also we included the
reaction of inhibition of PI3K by LY294002 (reaction 58).
Cross-talk between AKT and ERK branches
Since PP2A is a common phosphatase which deactivates both MEK and AKT, it can
be responsible for cross-talk between ERK and AKT signalling (103). In the original
model (103) the sharing of the common phosphatase PP2A was modelled by a quasi-
steady-state Michaelis-Menten approach by introduction of fraction coefficients
corresponding to the two branches. However Michaelis-Menten approach is not valid
at the concentration of the substrates (phosphorylated MEK or AKT), being
comparable with the concentration of the enzyme catalysing the reaction. To describe
directly cross-regulation of MEK and AKT activation by PP2A phosphatase sharing
we replaced the Michaelis-Menten approximation of PP2A reaction (103) with a
mass action model of PP2A interaction with active forms of AKT and MEK (see Fig.
S3). This modification permitted us to describe explicitly the competitive
deactivation ofMEK and AKT branches by common PP2A phosphatase.
Similarly we replaced the Michaelis-Menten approximation with mass action based
model for another key enzyme, PI3K (reactions V3|, V55, V56 in Figure Sib). This
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modification was made on base of experimental data on non-Michaelis-Menten
kinetics of PI3K catalysis (252).
The model also takes into account the cross-talk between AKT and ERK branches
due to RAF inactivation by AKT (103; 194;253): active AKT phosphorylates S259 on
Raf and inhibits its activity (reaction V12).
The results of the modelling are represented in Fig. S4 and the results of sensitivity
analysis are given in Fig. S5-S9.
Detailed kinetic model ofPTEN regulation
We developed a separate kinetic model of PTEN catalytic cycle and incorporated it
into the whole model. The model takes into account the following kinetic and
regulatory properties of PTEN: competition between lipid and protein phosphatase
activity of PTEN (254), autodephosphorylation activity of PTEN (229;255), balance
and interchange between PTEN and pPTEN [9], experimental data on kinetic
parameters of PTEN (256).
The developed catalytic cycle of PTEN is shown in Fig. S10. We took into account
that only the dephosphorylated form of PTEN possesses lipid phosphatase activity
(254). We used mass action approximation of rate equation of lipid phosphatase
activity on the base of experimental data on non-Michaelis-Menten kinetics of PTEN
(257).
The kinetic model of PTEN includes eight ODEs (S1.40)-(S1.47). The reactions V32-
34 describe the lipid phosphatase activity of PTEN, reaction V35 corresponds to
phosphorylation of PTEN by CK2 and GSK3. As phosphatase being responsible for
dephosphorylation of pPTEN is unknown (229), we considered
autodephosphorylation mechanism of pPTEN dephosphorylation (reaction V36-38)
due to its weak protein phosphatase activity (229). To analyse the function of the
proposed cycle of PTEN/pPTEN exchange we studied this model separately. Firstly,
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we simulated dynamic balance of PTEN/pPTEN in the absence of PIP3. In the result
the steady state concentrations of PTEN and pPTEN were determined in the system.
In our model the kinetic parameters of PTEN protein phosphatase activity and CK2
(GSK3) kinase were set in such a way that PTEN would be mainly in
dephosphorylated form.
We then studied effect of the substrate PIP3 on the PTEN/pPTEN balance. The
presence of PIP3 leads to the competition between PIP3 and CK3 (GSK3) for PTEN
that causes the decrease in free PTEN concentration due to formation of substrate-
enzyme complex PTENPIP3. It results in an elevation of pPTEN concentration due
to a slowdown in autodephosphorylation of pPTEN.
This model permitted us to describe a dynamic balance of PTEN/pPTEN in resting
cell and reproduce experimental data on increasing of pPTEN concentration during
AKT activation in PE04 ovarian carcinoma cells (see Figure S4d) and other cells
(258). Figure S4d shows the experimental and theoretical kinetics of pPTEN in the
absence/presence of pertuzumab. The comparison of the two kinetics in Figure S4d
shows that pertuzumab moderates pPTEN rise. According the model prediction this
effect is due to that PTEN consumption in lipid phosphatase reaction is lower at
signal inhibition than without inhibition. So, PTEN mainly participates in
autodephosphorylation reaction in this case and enhances dephosphorylation of
pPTEN.
Thus the model predicts the kinetics of pPTEN may indicate the decrease of PTEN
lipid activity (in the case of PTEN inhibition) or activation of PTEN/PI3K cycle due
to PI3K activation. According to the model the loss of PTEN lipid phosphatase
activity causes the decrease of pPTEN level as well as PI3K activation leads to the
increasing of pPTEN concentration compared to normal PTEN/PI3K cycle function.
B.3 Mechanism of resistance to RTK inhibitors
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Here, we analysed how sensitivity of the cancer signalling depends on PTEN/PI3K
cycle. Such types of cycles comprising two interconvertible enzymes, kinase and
phosphatase were extensively analysed previously(231;232).
We found that integrative parameter y= PTEN/PI3K* is responsible for sensitivity,
where PTEN and PI3K* are the enzyme activities calculated as the ratio Vma/Km,
where Vmax=kCate - maximum velocity, kcat - catalytic constant, e - enzyme
concentration, Km=(k.i+kcat)Ai= Kd+ kC(l,/ki - Michaelis constant, Kj - dissociation
constant, yo =105 (resulted from fitting to experimental Fig. 2a). The y could be
changed as a result of the enzyme inhibition, variations in enzyme expression level
(e), and mutations causing changes in catalytic constantly,) and/or affinity (Kd).
We compared the responses of the system to heregulin stimulation in the presence
and absence of pertuzumab (see Fig. 2a and Fig. S6a) in the range of y.
At the values of the parameter y near y0 (see Fig. 2b) the system discriminates input
signals, i.e. output signal (pAKT) is proportional to the input signal (pHER2). In this
regime the PTEN/PI3K cycle functions as a discriminator of the receptor signals.
PTEN/ PI3K cycle switches to amplification regime when y decreases 5-10 times, i.e.
the system amplifies all input signals pHER2 up to maximal output signal pAKT. In
this regime the system becomes insensitive to the external signal. We propose that
this amplification regime corresponds to resistance in RTK signal inhibition. Our
theoretical results predict (Fig. SlOd) that combination of two inhibitors (RTK and
PIK3 inhibitors) could prevent the drug resistance caused by the loss of PTEN
activity as it would lead to an increase yback to normal y0 . We found that the PTEN/
PI3K cycle could exhibit a signal suppression at the high value of y (ten times higher
than y0). Such higher values of y can be reached in the system, for example, by
inhibition of PI3K.
To demonstrate the suppression regime we used experimental data on inhibition of
PI3K by LY294002 (see Fig. S9). Fig. SlOc shows the predicted kinetics of pAKT
signal induced by HRG in the absence and presence of PI3K inhibitor. PI3K
inhibition causes weakening of the pAKT signal to zero level, i.e. the PTEN/ PI3K
cycle inhibits the signal transduction from RTK receptors.
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Appendix C: Mathematical model ordinary differential equations.
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where reaction rates V) are determined by the following equations:
V,=k, ([E3] [HRG]-Kdl [E3HJ) (SI.57)
V2 =k2 • ([E3HJ • [E2] - Kd2 • [E23H]) (S1.58)




V5 =k5 • ([pE23H] • [She] - Kd 5 • [pE23H-Shc]) (S1.61)
V6 =k6 • [pE23H-Shc] - k 6 • [pE23H-pShc] (S1.62)
V7 =k7 • ([pE23H-pShc] ■ [GS] - Kd 7 • [pE23H-pShc-GS]) (S1.63)
Vg =kg • ([pE23H-Shc-GS] - Kd g • [pE23HP] • [Shc-GS]) (S1.64)
V9 =k9 • [Shc-GS] - k_9 • [pShc] • [GS] (S1.65)
V10=Vmax.10 -[pShc] / (Kml0 + [pShc]) (SI.66)
Vn=kn • [Ras-GDP] • [Shc-GS]/(Km n +[Ras-GDP]) (S1.67)
V12=V]2 [Ras-GTP]/(Kml2+[Ras-GTP]) (SI.68)
V13=k13 • [Raf]• [Ras-GTP]/(Km l3 +[Raf|) (S1.69)
V14=kl4 • [Raf*] • ([ppAkt-PIP3]+[ERaf ])/([Raf*]+Km 14) (S1.70)




V19=kl5 • [pMEK]• [Raf*]/(Kml5 +[pMEK]) (SI.75)
V20=k16-([PP2A]-[ppMEK] -Kdl6 [ppMEK-PP2A]) (S1.76)
V21 =kcat l6 • [ppMEK-PP2A] (S1.77)
V22 =k 22 • [pMEK-PP2A] (S1.78)
V23=k23 [ERK] [ppMEK]/(Km23+[ERK]) (SI.79)
V24 =Vmax 24 • [pERK]/(Km 24+[pERK]) (S1.80)
V25 =k23 [ppMEK]• [pERK]/(Km23+[pERK]) (S1.81)
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V^vmax.24 • [ppERK]/(Km.24 -HppERK]) (S1.82)
v2>^27 * ([pE23H] • [PI3K] - Kd27.[pE23H-PI3K]) (S1.83)
V2^k28-[pE23H-PI3K]-£_28-[pE23H-PI3K*] (SI.84)
v2^29 •fpE23H-PI3K*]-k-29 fpE23H-PI3K*l (S1.85)
V3^K30-[PI3K*] (SI.86)
v3, ^k3, ([PI] [PI3K*] - Kdj3i • [PI3KKPI]) (S1.87)
v35^k32 * ([PIP3] • LPTEN]- Kd32 • [PTEN-PIP3]) (S1.88)
V3^K33 [PTEN-PIP3] (SI.89)
V3^K34-[PTEN-PI] (SI.90)
=*Vmax.35 ' [PTEN]/(Km35 +[PTEN]) (S 1.91 )
V3^^k36 • ([PTEN] • fpPTEN] - Kd36 • [pTENP-PTEN]) (S1.92)
\ cat.37 • [pPTENP-PTEN] (S1.93)
V3^k38[PTEN-PTEN] (S1.94)
V3S=k39 • ([PIP3] • [Akt]- Kd39 • [Akt-PIP3]) (S1.95)
\^vmax.40 •[Akt-PIP3]/(Km40+[Akt-PIP3]) (SI.96)
V4, ^k4, • [pAkt-PIP3] • [PP2A] (S1.97)
^kca,.42 • [pAkt-PIP3-PP2A] (S1.98)
v43 =k43 • [ Akt-PIP3-PP2A] (S1.99)
V4^Vmax4Q .[pAkt-PIP3J/(Km40+[pAkt-PIP3]) (SI.100)
=k45 • ([ppAkt-PIP3] • [PP2A]- Kd,45 • [ppAkt-PIP3-PP2A]) (S1.101)






V45 =k49 • ([2C4] • [E2] - Kd49 • [E2-2C4]) (SI. 105)
\ s=kS0 • [E2-2C4] - k.50 • [E2-2C4c ] (SI. 106)
V5,^K5, tH3HJ (SI. 107)
^K2 • ([E3Hc]• |E2]- Kd2 ■ |E23H]) (SI. 108)
V5^K53tE23H] (SI. 109)
V5^K3-(tE23HJ- Kd3• [pE23H]) (Sl.l 10)
V5s^KS5 [PI3K*-PI] (SI.111)
V5^k56|PI3K*-PIP3] (SI.112)
V5^K5v -([PTEN] [bpV]- Kd57 .[PTEN_bpVJ) (Sl.l 13)
V5&^k58 ([PI3K][LY]- K458 [PI3K_LY]) (Sl.l 14)
C.2 Abbreviations used in the model.
Abbreviations in Protein names Abbreviations in
text, ODEs, schemes SBML file
E2, HER2 ErbB2 receptor E2
E3, HER3 ErbB3 receptor E3
HRG Heregulin HRG
E3H ErbB3/HRG ligand/receptor complex E3H
E3HC ErbB3/HRG ligand/receptor complex E3H C
E23H Heterodimer of ErbB3/HRG with ErbB2 E23H
E23HC Heterodimer of ErbB3/HRG with ErbB2 E23H_C
pE23H, pHER2 Phosphorylated heterodimer of
ErbB3/HRG with ErbB2
E23HP
Grb2 growth factor receptor-binding protein 2
Ras-GDP Ras-GDP protein RasGDP
Ras-GTP Ras-GTP protein RasGTP
Raf Raf protein Raf
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Raf* Activated Raf Rafa
PTEN Phosphatase and tensinhomologue
deleted on chromosome ten
PTEN
pPTEN Phosphorylated PTEN PTENP
AKT AKT protein Akt
2C4 Pertuzumab Per
MAPK Mitogen-activated protein kinase
MEK MAPK/ERK kinase
pMEK Phosphorylated MEK MEKP
ppMEK Doubly phosphorylated MEK MEKPP
ERK extracellular signal-regulated kinase
pERK Phosphorylated ERK ERKP
ppERK Doubly phosphorylated ERK ERKPP
MKP3 MAPK phosphatase 3
PDK1 3-phosphoinositide-dependent kinase 1
PI phosphatidylinositol PI
PIP3 phosphatidylinositol-3,4,5-trisphosphate
PI3K phosphatidylinositol 3' -kinase PI3K
PI3K* Activated PI3K PI3Ka
PP2A protein phosphatase 2A PP2A
She Srchomology and collagen domain
protein
She
pShc Phosphorylated She ShcP
Sos Son of Sevenless homologue protein
GS Grb2-Sos complex GS
pE23H-Shc Complex of pE23H with She E23HP_Shc
pE23H-pShc Complex of pE23H with pShc E23HP_ShP
Shc-GS Complex of She with GS ShGS
pE23H-pShc-GS Complex of pE23H-pShc with GS E23HP_ShGS
AKT-PIP3 Complex of AKT with PIP3 AKT_PIP3
pAKT-PIP3 Complex of pAKT with PIP3 AKT_PI_P
ppAKT-PIP3 Complex of ppAKT with PIP3 AKT_PI_PP
ppAKT-PIP3-PP2A Complex of ppAKT-PIP3 with PP2A AKT_PI_PP_PP2A
AKT-PIP3-PP2A Complex of AKT-PIP3 with PP2A AKT_PIP3_PP2A
pAKT-PIP3-PP2A Complex of pAKT-PIP3 with PP2A AKT_PI_P_PP2A
E2-2C4 Complex of E2 with 2C4 E2_Per
E2-2C4c Complex of E2 with 2C4 E2Per
PTEN-PTEN Complex of PTEN with PTEN PTEN_PTEN
pPTEN-PTEN Complex of pPTEN withPTEN PTENP_PTEN
PTEN-PIP3 Complex of PTEN with PIP3 PTEN_PIP3
PTEN-PI Complex of PTEN with PI PTEN_PI
pMEKP-PP2A Complex of pMEKP with PP2A MEKP_PP2A
MEK-PP2A Complex ofMEK with PP2A MEK PP2A
ppMEKPP-PP2A Complex of ppMEKPP with PP2A MEKPP_PP2A
pE23H-PI3K Complex of pE23H with PI3K E23HP_PI3K
PI3K*-PI Complex of PI3K* with PI PI3Ka_PI
pE23H-PI3K* Complex of pE23H with PI3K* E23HP_PI3Ka
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LY LY294002, PI3K inhibityor LY
PTEN-bpV Enzyme-inhibitor complex of PTEN and
bpV(pic)
PTEN_bpV
PI3K-LY Enzyme-inhibitor complex of PI3K and
LY294002
PI3K_LY
C.3 Kinetic parameters of the model.
kj, k.j- rate constants of forward and reverse reactions, nM'1 min"1, Kd,i, Km<i-











HER3 and HER2 binding
v, k, 0.005 0.001 0.003
Kd,i 600; 0.2" 0.6 20
V5, ksi 0.01
V2 k2 10 0.01 0.01
V52 Kd,2 10±42) 10 10
V53 k53 0.01
V3 k3 1±0.2 1 1
Kd.3 0.1 ±0.04 0.01 0.01
V4 Vmax.4 10±4 62 450
Km,4 50±30 50 50
She and GS binding
v5 k5 0.06±0.01 0.1 0.09
Kd,5 1 1 6
V6 k6 12 20 6
k-6 3 5 0.06
V7 k7 36 60 0.009
Kd,7 9 9 4.3
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V8 k8 12 2040 0.12
Kd,8 0.1 7.8 0.002
V9 k9 35±4 40.8 0.1
k-9 0 0 0.2
V10 Vmax, 10 0.0154 0.0154 1.7
Km,10 340 340 340
E23HP binding with PI3K and PI3K activation
V27 k27 3±1 0.1
Kd,27 1 20
V28 k28 300±30 9.85
k-28 0 0.1
V29 k29 13500 45.8
k-29 0 0.047
V30 V30 9001130 Vm,26=2620
Ras/Raf/MEK/ERK cascade
V,, ki 1 610.6 0.22
Km. 11 0.18 0.18
V12 Vmax, 12 310.5 0.3
Km, 12 0.1 0.06
V13 kl3 110.2 1.53
Km, 13 11.7 11.7
V ,4 ki4 0.610.3 6.7 10"J
Km, 14 30115 8
V,5V,9 kis 2.110.3 3.5
Km, 15 110.5 317
V ,6 kl6 0.06
V17 ,V21 kcat,l6 0.6






V23V25 k23 1.2±0.05 9.5
Km,23 10±0.7 1.4 105



















v39 k39 15000 507
Kd,39 2016 234
V40 V44 Vmax,40 1500015000 2 104
Km,40 0.110.035 8 104
V41 k41 3







v48 00 0.001 0.001
2C4 binding
V49 k49 0.003















" the value of the parameters after rescaling of HRG and 2C4 concentrations to
extracellular volume.
2) absolute errors show the deviation of the parameter giving 5% deviation of the
output signal (pHER2, pAKT, pERK) which possesses most sensitivity to this
parameter. The errors are given only for the parameters having sensitivity more than
0.04 (see Fig. S5-S9).
Table S3. Initial concentrations of the metabolites in the model, nM
Metabolites Values in
our model
Remarks Values from [1] Values from [2]
HER3 80±3 HER4=80 EGFR=100
HER2 100±10
HRG 100 100

















Appendix D: Supplementary figures for mathematical model.
159
D.1: Supplementary Figures and Legends.
2C4






^ PI3K*-PIP3 V; PI3K* b
Supplementary figure SI. a - Scheme of the two-step mechanism of the binding of
the receptor HER2 (E2) with ligand. pertuzumab (2C4). b - Detailed scheme of the







Supplementary figure S2. Detailed scheme of heterodimerisation of HER3 (E3) and
HER2 (E2) receptors along with formation of the transphosphorylated complex,
160
Appendix D
pE23H. Reactions Vi, V51 corresponds to a two-step mechanism of the binding of
HER3 (E3) receptor and heregulin (HRG) with a formation of the intermediate, E3H
and the final E3HC ligand-receptor complex. Reactions V2, V52, and V53 describe the
two-step mechanism of heterodimerisation of HER3 (E3) and HER2 (E2) receptors
leading to formation of intermediate E23H and final E23HC heterodimer. Reactions
V3 and V54 describe transphosphorylation of E23H and E23HC heterodimers with




Supplementary figure S3. Detailed scheme of dephosphorylation of pMEK
(reactions V]6, V|7, Vi8), ppMEK (reactions V20, V2), V22), pAkt (reactions V4|, V42,
V43), ppAkt (reactions V45, V46, V47) by the phosphatase PP2A.
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Supplementary figure S4. Time-course plots of computational simulations (bold
lines) and experimental data (points) in the PE04 cell line showing the effect and
heregulin-3 (black) and pertuzumab (blue) on kinetics of pHER2 (a), pAKT (b), and
pERK (b), pPTEN (c) and matching of experimental data with model simulations,
















Supplementary figure S5. Sensitivity Spher: of pHER2 to kinetic parameters of the
reactions (1-4, 51, 53, see Figure 6.1) (a) and initial concentrations of the enzymes
(b) involved in HER3/HER2 heterodimerisation and autophosphorylation.





'd,3i *55 k56 k32 Kd32 k33 k34 k39 ^d.39 ^40 ^40 k41 Kd 41 k42 k43 k47
Supplementary figure S6. Sensitivity Spakt of pAKT to kinetic parameters of the
reactions involved in HER3/HER2 heterodimerisation and autophosphorylation
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(reactions 1-4, 51, 53) (a); PI3K activation (reactions 27-30) (b); PI3K/PTEN cycle
(reactions 31-34) (c); and AKT phosphorylation (reactions 39-47) (d).
Supplementary figure S7. Sensitivity Spakt of pAKT to kinetic parameters of
reactions (35-38) involved in PTEN/pPTEN cycle (a) and initial concentrations of




Supplementary figure S8. Sensitivity Sperk of pERK to kinetic parameters of the
reactions involved in HER3/HER2 heterodimerisation and autophosphorylation
(reactions 1-4, 51,53) (a); the formation of Shc-GS complex (reactions 5-10) (b); and
the Ras/RAF/MEK/ERK pathway (reactions 11-26) (c).
1 1 1 i 1 1 1 i i 1 1 1 1 i r
HER3 HER2 HRG She GS Ras Raf MEK ERK PI3K AKT PP2A PI2 PTEN















Supplementary figure S10. Catalytic cycle of PTEN with lipid phosphatase activity














0 10 20 30 40 50 60
Time, min
C
Supplementary figure Sll: Theoretical results illustrating the mechanism of the
resistance to pertuzumab (2C4) due to the loss of PTEN activity. Computational
kinetics of PI consumption (a, c) in the PTEN/PI3K cycle and pAKT signal (b, d) at
different levels of PTEN activity in the absence of 2C4 (black lines) and presence of
100 nM of 2C4. (a, b) - inhibition effect of 2C4; (c,d) - resistance to 2C4 due to
PTEN inhibition by bpV. Concentration of pAKT is given in relative units.
1 50 nM bpV
&— no 2C4


















Supplementary figure S12: Time course experiments profiling the phosphorylation
of PI3K and MAPK signalling molecules for computational model validation.
Figures are representative of qualitative changes in activation state generated from
three experimental replicates and different detection methods (western blotting and














Supplementary figure S13: Experimental and theoretical dose-response of pAKT to
heregulin-P at 5 and 30 minutes.
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pAKT activity in Unstimulated PH>4 cells treated with HB3(1nM) V-
LY294002 at 1*M 5^1,10^ aid 25{jM
pBKactivity in l-R5-stimulated PB)4 cells treated with HRG(1nM) +/-

















Supplementary figure S14: Inhibition of PI3K with LY294002 (LY) results in
dose-dependent inhibition of pAKT, but not pERK, in response to heregulin (a,b). c -
theoretical kinetics of pAKT at the different concentration of LY294002 (lines),
points - experimental data, d - Suppression of the resistance to pertuzumab (2C4) by
PI3K inhibition. pAKT kinetics in the presence of bpV and 2C4 (black line); bpV,
2C4, and LY294002 (blue line); bpV, LY294002 (red line), e - pAKT dose-
dependence on LY294002 in the absence and presence of bpV (50 uM) for 30 min.
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Supplementary figure S15: Computational analysis of MAPK-PI3K network
predicts that PTEN loss (a), PIK3CA mutation (b), and HER2 overexpression (c) will























Supplementary figure S16: Relative expression of HER 1^4 in BT474 and PE04
cell lines.
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